Dietary Reference Values for choline:(Scientific Opinion) by Sjödin, Anders Mikael
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Dietary Reference Values for choline
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
Published in:
E F S A Journal
DOI:
10.2903/j.efsa.2016.4484
Publication date:
2016
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) (2016). Dietary Reference Values for choline:
(Scientific Opinion). E F S A Journal, 14(8), [4484]. https://doi.org/10.2903/j.efsa.2016.4484
Download date: 03. Feb. 2020
SCIENTIFIC OPINION
ADOPTED: 21 April 2016
doi: 10.2903/j.efsa.2016.4484
Dietary Reference Values for choline
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
Abstract
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) derives Dietary Reference Values (DRVs) for choline. In this Opinion, the
Panel considers dietary choline including choline compounds (e.g. glycerophosphocholine,
phosphocholine, phosphatidylcholine, sphingomyelin). The Panel considers that none of the biomarkers
of choline intake or status is suitable to derive DRVs for choline. The Panel considers that Average
Requirements and Population Reference Intakes for choline cannot be derived for adults, infants and
children, and therefore deﬁnes Adequate Intakes (AIs). For all adults, the Panel sets an AI at 400 mg/day
based on the average observed choline intake in healthy populations in the European Union and in
consideration of the amounts of choline needed to replete about 70% of depleted subjects who
showed signs of organ dysfunction in a depletion/repletion study. For all infants aged 7–11 months,
the Panel proposes an AI of 160 mg/day, based on upwards extrapolation from the estimated choline
intake of exclusively breast-fed infants from birth to 6 months. For all children aged 1–17 years, the
Panel proposes AIs, based on downwards extrapolation from the adult AI, applying growth factors.
These AIs range from 140 mg/day (1–3 years) to 400 mg/day (15–17 years). For pregnant women,
the Panel derives an AI of 480 mg/day, calculated by extrapolation from the AI for non-pregnant
women and the mean gestational increase in body weight. For lactating women, the amount of choline
secreted per day in human milk during the ﬁrst 6 months of exclusive breastfeeding (120 mg/day) is
added to the AI for non-lactating women and an AI of 520 mg/day is set.
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Summary
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to deliver a Scientiﬁc Opinion on Dietary Reference Values (DRVs) for
the European population, including choline.
Choline is a quaternary amine (2-hydroxyethyl-N,N,N-trimethylammonium) present in food in free and
esteriﬁed forms. The main forms present in foods are phosphatidylcholine (PC, lecithin), which is also the
main form present in animal tissues, free choline, phosphocholine (PChol), glycerophosphocholine (GPC)
and sphingomyelin (SPM), and minor amounts of cytidine-5-diphosphate-choline (CDP-choline) and
acetylcholine. Choline, PChol and GPC are water-soluble choline compounds, whereas PC and SPM are
lipid-soluble compounds.
Although choline can be synthesised de novo by the human body, this synthesis may
become insufﬁcient, making choline an essential component of the diet. Choline is predominantly
provided via the diet. The human body can form choline either de novo by methylation of
phosphatidylethanolamine (PE) via the hepatic phosphatidylethanolamine N-methyltransferase (PEMT)
pathway, or by hydrolysis of PC formed in the CDP-choline pathway in all cells of the body. The PC
formed in the PEMT pathway contains substantial amounts of long-chain polyunsaturated fatty acids,
like docosahexaenoic acid and arachidonic acid. Both pathways can be stimulated by dietary choline
and the PEMT pathway is sensitive to the presence of oestrogens. Choline is an integral part of some
phospholipids, which play an important role in the structure and function of membranes. Choline (as
PC) plays an important role in the metabolism and transport of lipids and cholesterol by lipoproteins,
and is needed for the assembly and secretion of very low-density lipoproteins by the liver. Choline is a
precursor of the neurotransmitter acetylcholine, and of betaine, an osmoregulator to which choline is
irreversibly oxidised in the liver and kidney. Via betaine, choline is involved in the folate-dependent
one-carbon metabolism. Dietary deﬁciency of choline can cause fatty liver or hepatic steatosis that can
result in non-alcoholic fatty liver disease (NAFLD), and can cause liver and muscle damage. This shows
that de novo production can be insufﬁcient.
Dietary free choline is quickly taken up by a carrier-mediated saturable transport system. PC and
GPC from the diet or secreted in the bile, and dietary SPM are hydrolysed by phospholipases (PLs) to
liberate choline. Choline and water-soluble choline compounds (PChol and GPC) are rapidly absorbed
and appear in plasma predominantly as free choline. Phospholipids (PC and SPM) that have escaped
PLs enter the lymph incorporated into chylomicrons. The available data do not allow deﬁning the
percentage of intestinal absorption of choline in humans, and the total amount of choline in the human
body. Non-absorbed choline is a precursor of trimethylamine (TMA) produced in the gut by anaerobic
symbiotic microbes. TMA is efﬁciently absorbed from the gastrointestinal tract and then converted in
the liver to trimethylamine-N-oxide (TMAO). Both TMA and TMAO (i.e. total trimethylamine (TTMA))
are eliminated in the urine. Urinary excretion of choline is low in relation to usual dietary intakes, while
no human data are available on faecal excretion of choline or choline compounds in relation to dietary
intake. Breast milk mainly contains PChol and GPC, besides free choline, PC and SPM, in concentrations
depending on the progress of lactation, maternal diet and genotype.
The Panel reviewed possible biomarkers of choline intake and/or status. The Panel considers that
the available data do not allow conclusions to be drawn on a dose–response relationship between
choline intake or status and plasma choline concentration, and that plasma choline concentrations
cannot be used to set DRVs for dietary choline. Plasma concentrations of PC, betaine, dimethylglycine,
total homocysteine or TMAO, erythrocyte PC concentration, or urinary betaine and TTMA urinary
excretion also cannot be used to set DRVs for dietary choline. The Panel also notes that single-
nucleotide polymorphisms in genes coding for enzymes involved in choline metabolism, some of them
present with high frequency in the population, can inﬂuence the dietary requirement for choline and
determine the susceptibility to dietary choline deﬁciency, but data are insufﬁcient to predict variations
in individual choline requirements based on genetic polymorphisms. The Panel considers that the
available data on choline intake and health consequences (NAFLD, cardiovascular disease, cancer, birth
defects, cognition) cannot be used to set DRVs for dietary choline.
The Panel considers that Average Requirements and Population Reference Intakes for choline
cannot be derived for adults, infants and children, and therefore deﬁnes Adequate Intakes (AIs).
Dietary total choline intake was calculated based on individual food consumption data that were
available to the European Food Safety Authority (EFSA) and classiﬁed according to EFSA’s food
classiﬁcation system, from healthy populations investigated in 12 national surveys undertaken in nine
countries of the European Union (EU), between 2000 and 2011. In the absence of food composition
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data on choline in Europe, composition data on free choline and choline compounds from the US
Department of Agriculture were used. The total choline intake mean estimates ranged from 75 to
127 mg/day in infants, from 151 to 210 mg/day in children aged from 1 to < 3 years, from 177 to
304 mg/day in children aged from 3 to < 10 years, and from 244 to 373 mg/day among children aged
from 10 to < 18 years. The total choline intake mean estimate was 336 mg/day in pregnant
adolescents and 356 mg/day in pregnant women. The total choline intake mean estimates ranged
from 269 to 444 mg/day and from 332 to 468 mg/day in women and men, respectively, i.e. for all
adults: 269–468 mg/day.
The Panel reviewed 11 choline depletion/repletion studies with similar design. Only one reported
the amounts of choline needed to replete depleted subjects who showed signs of organ dysfunction.
The Panel concludes that choline depletion/repletion studies do not provide sufﬁcient data to calculate
Average Requirements for choline, but may be used to inform data on observed choline intakes to set
AIs for choline.
For all adults, the Panel set an AI of 400 mg/day. This is based on the midpoint of the range of
observed mean intakes in healthy populations in the EU (about 370 mg/day), and in consideration of
the results of a depletion/repletion study in which about 70% of the depleted subjects who had
developed signs of organ dysfunction were repleted with an intake of about 400 mg/70-kg body
weight (bw) per day. Although premenopausal women may have a lower requirement for dietary
choline (than postmenopausal women or men) in connection with a potential stimulation of the PEMT
pathway by oestrogens, and ranges of estimated mean total choline intake in Europe are slightly lower
in women than men, the Panel considered it unnecessary to give sex-speciﬁc AIs for adults.
For infants aged 7–11 months, the Panel set an AI of 160 mg/day, based on the estimated intake
of choline of exclusively breast-fed infants from birth to 6 months, and upwards extrapolation by
allometric scaling, taking into account the difference in reference body weight.
For all children aged 1–17 years, no data are available that would justify different AIs for boys and
girls. The Panel set AIs ranging from 140 mg/day (1–3 years) to 400 mg/day (15–17 years). These
were set by downwards extrapolation from the adult AI, by allometric scaling, taking into account the
difference in reference body weight and applying growth factors. These AIs are supported by total
choline intake mean estimates in the EU.
The Panel considered that, although the available intervention studies on choline supplementation
in the second half of pregnancy or in lactating women indicate that pregnant or lactating women may
need more choline than non-pregnant non-lactating women, the data are not sufﬁcient to allow an
estimate of the additional requirement for dietary choline in pregnant or lactating women (above that
of non-pregnant non-lactating women).
For pregnant women, the Panel set an AI of 480 mg/day, calculated by isometric scaling from the
AI for non-pregnant women, using the mean gestational increase in body weight. For lactating
women, the AI for non-lactating women is increased to account for the secretion of choline through
breast milk. The Panel set an AI of 520 mg/day, considering an average concentration of choline in
mature breast milk of 145 mg/L, and a mean milk transfer during the ﬁrst 6 months of lactation in
exclusively breastfeeding women (0.8 L/day).
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Background as provided by the European Commission
The scientiﬁc advice on nutrient intakes is important as the basis of Community action in the ﬁeld
of nutrition, for example such advice has in the past been used as the basis of nutrition labelling. The
Scientiﬁc Committee for Food (SCF 1993) report on nutrient and energy intakes for the European
Community dates from 1993. There is a need to review and if necessary to update these earlier
recommendations to ensure that the Community action in the area of nutrition is underpinned by the
latest scientiﬁc advice.
In 1993, the SCF adopted an opinion on the nutrient and energy intakes for the European Community.1
The report provided Reference Intakes for energy, certain macronutrients and micronutrients, but it
did not include certain substances of physiological importance, for example dietary ﬁbre.
Since then new scientiﬁc data have become available for some of the nutrients, and scientiﬁc
advisory bodies in many European Union (EU) Member States and in the United States have reported
on recommended dietary intakes. For a number of nutrients, these newly established (national)
recommendations differ from the reference intakes in the SCF (1993) report. Although there is
considerable consensus between these newly derived (national) recommendations, differing opinions
remain on some of the recommendations. Therefore, there is a need to review the existing EU
Reference Intakes in the light of new scientiﬁc evidence, and taking into account the more recently
reported national recommendations. There is also a need to include dietary components that were not
covered in the SCF opinion of 1993, such as dietary ﬁbre, and to consider whether it might be
appropriate to establish reference intakes for other (essential) substances with a physiological effect.
In this context, EFSA is requested to consider the existing Population Reference Intakes for energy,
micro- and macronutrients and certain other dietary components, to review and complete the SCF
recommendations, in the light of new evidence, and in addition advise on a Population Reference
Intakes for dietary ﬁbre.
For communication of nutrition and healthy eating messages to the public, it is generally more
appropriate to express recommendations for the intake of individual nutrients or substances in food-
based terms. In this context, EFSA is asked to provide assistance on the translation of nutrient-based
recommendations for a healthy diet into food-based recommendations intended for the population as a whole.
Terms of reference as provided by the European Commission
In accordance with Article 29 (1)(a) and Article 31 of Regulation (EC) No 178/20022, the
Commission requests EFSA to review the existing advice of the Scientiﬁc Committee for Food on
Population Reference Intakes for energy, nutrients and other substances with a nutritional or
physiological effect in the context of a balanced diet which, when part of an overall healthy lifestyle,
contribute to good health through optimal nutrition.
In the ﬁrst instance, EFSA is asked to provide advice on energy, macronutrients and dietary ﬁbre.
Speciﬁcally, advice is requested on the following dietary components:
• Carbohydrates, including sugars;
• Fats, including saturated fatty acids, polyunsaturated fatty acids and monounsaturated fatty
acids, trans fatty acids;
• Protein;
• Dietary ﬁbre.
Following on from the ﬁrst part of the task, EFSA is asked to advise on population reference intakes
of micronutrients in the diet and, if considered appropriate, other essential substances with a
nutritional or physiological effect in the context of a balanced diet which, when part of an overall
healthy lifestyle, contribute to good health through optimal nutrition.
Finally, EFSA is asked to provide guidance on the translation of nutrient-based dietary advice into
guidance, intended for the European population as a whole, on the contribution of different foods or
categories of foods to an overall diet that would help to maintain good health through optimal
nutrition (food-based dietary guidelines).
1 Scientiﬁc Committee for Food, Nutrient and energy intakes for the European Community, Reports of the Scientiﬁc Committee
for Food 31st series, Ofﬁce for Ofﬁcial Publication of the European Communities, Luxembourg, 1993.
2 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety. OJ L 31, 1.2.2002, p. 1–24.
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Assessment
1. Introduction
Choline is a water-soluble organic compound needed for normal functioning of the body. Although
choline can be synthesised de novo by the human body, this synthesis may become insufﬁcient,
making choline an essential component of the diet (Ueland, 2011).
In 1993, the SCF adopted an opinion on nutrient and energy intakes for the European Community
and considered that there was no evidence for the necessity of an intake of choline via the diet for
persons older than 6 months (SCF, 1993). As it was unclear if young infants depend on exogenous
sources of choline and because choline is an integral component of human milk, the addition of choline
to infant formula with a minimum level of 7 mg of choline/100 kcal was made mandatory.3
The purpose of this Opinion is to review the available evidence to assess whether it might inform
the setting of Dietary Reference Values (DRVs) for choline. The Panel focuses in this Scientiﬁc Opinion
on dietary choline including choline containing compounds.
2. Deﬁnition/category
2.1. Chemistry
Choline, 2-hydroxyethyl-N,N,N-trimethylammonium (2-hydroxy-N,N,N-trimethylethanamonium, IUPAC,
molar mass 104.17 g/mol) is a quaternary amine. In foods, it is present as free choline and in esteriﬁed
forms, mainly as phosphatidylcholine (PC, lecithin), phosphocholine (PChol), glycerophosphocholine (GPC)
and sphingomyelin (SPM) (Figure 1), and minor amounts of cytidine-5-diphosphate-choline (CDP-choline)
and acetylcholine (Ueland, 2011). PC accounts for approximately 95% of total choline found in animal
tissues. Choline, PChol and GPC are water-soluble choline compounds, whereas PC and SPM are lipid soluble.
Choline is a component of some phospholipids. Phospholipids are derived from either glycerol or
sphingosine, an amino alcohol with a long unsaturated hydrocarbon chain (C18). Phosphoglycerides
consist of a glycerol of which the hydroxyl groups at C1 and C2 are esteriﬁed to the carboxyl groups of
two fatty acids, while the hydroxyl group at C3 is esteriﬁed to PChol (or other phosphorylated alcohols
derived from ethanolamine, serine or inositol). SPM consists of sphingosine, which amino group is
linked to a fatty acid by an amide bond and which primary alcohol group is esteriﬁed to PChol.
Choline Glycerophosphocholine (GPC) Phosphocholine (PChol)
Phosphatidylcholine (PC) Sphingomyelin (SPM)
Figure 1: Chemical formulas of choline, glycerophosphocholine, phosphocholine, phosphatidylcholine
and sphingomyelin
3 Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending Directive
1999/21/EC, OJ L 401, 30.12.2006, p. 1.
Dietary Reference Values for choline
www.efsa.europa.eu/efsajournal 8 EFSA Journal 2016;14(8):4484
2.2. Function of choline
2.2.1. Biochemical functions
Choline has a number of important functions: it is a precursor for the phospholipid PC
(Section 2.1); it is involved in the metabolism and transport of lipids and in the folate-dependent one-
carbon metabolism; and it is a precursor of acetylcholine and of betaine.
Choline is an integral part of some phospholipids (Section 2.1). Phospholipids are abundant in all
biological membranes (40–50% of phospholipids of cellular membranes consist of PC (Zeisel, 2006)),
where they play an important role in the structure and function of membranes, including signalling and
transport, and they are also a constituent of the surfactant complex in the lung (Dushianthan et al., 2014).
Choline plays an important role in the metabolism and transport of lipids and cholesterol. PC makes
up 70–95% of phospholipids in lipoproteins (Zeisel, 2006) and is needed for normal assembly and
secretion of very low-density lipoproteins (VLDL) in the liver (Vance et al., 2007).
Choline is acetylated in cholinergic neurons to form acetylcholine, a key neurotransmitter involved in
functions like memory storage and muscle control (IOM, 1998; Ueland, 2011). Pre- and postnatal choline
availability has been shown to be important for neurodevelopment in animals (Meck and Williams, 2003).
In the liver and kidney, choline is irreversibly oxidised, by a mitochondrial choline oxidase (also called
choline dehydrogenase (CHDH)) and betaine aldehyde dehydrogenase (BADH), to betaine (Lin and Wu,
1986) (Sections 2.3.5.2.1 and 2.3.5.2.2). Betaine serves as an osmoregulator and is a substrate in the
betaine-homocysteine methyltransferase (BHMT) reaction. This reaction links choline and betaine to the
folate-dependent one-carbon metabolism (Figure 2, Sections 2.3.5 and 2.3.7). Choline and betaine are
important sources of one-carbon units, in particular during folate deﬁciency (Ueland, 2011). In
remethylating homocysteine (Hcy) to methionine, choline contributes, via betaine, to the availability of
S-adenosyl-methionine (SAM) as the universal methyl-group donor (Figure 2, Section 2.3.5). For
example, the methyl group of SAM can be transferred to cytosine residues adjacent to guanine (CpG) of
DNA or to histones at speciﬁc lysine sites, thereby contributing to epigenetic modiﬁcation and potentially
exerting effects on gene expression (Mehedint and Zeisel, 2013).
2.2.2. Health consequences of deﬁciency and excess
2.2.2.1. Deﬁciency
Dietary deﬁciency of choline can cause fatty liver (hepatic steatosis, which can result in non-alcoholic
fatty liver disease (NAFLD)) (Buchman et al., 1995), and liver (Zeisel et al., 1991) and muscle damage as
indicated by an increase in creatine phosphokinase (CK) concentration in serum (Fischer et al., 2007).
Hepatic steatosis may be due to impaired triacylglycerol (TAG) transport out of the liver. As PC is an
essential component of VLDL, the lipoprotein responsible for transporting TAG out of the liver
(Section 2.2.1), TAG cannot be exported in case of choline deﬁciency and accumulates in the
hepatocytes (Cole et al., 2012). Hepatic steatosis can progress to liver damage with release of liver
enzymes into the blood. This release of enzymes from the liver into the blood may follow induction of
apoptosis and cell membrane fragility (da Costa et al., 2006a; Fischer et al., 2007). In serum of 41 long-
term parenterally fed subjects, both alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) concentrations were signiﬁcantly and negatively associated with the concentration of free choline
(r = 0.34, p = 0.03; r = 0.37, p = 0.02, respectively), but not with that of phospholipid-bound
choline (Buchman et al., 1993). In this study, the concentration of free choline in serum was low, i.e.
one-third of the reference values used by the authors, while that of PC was normal.
The susceptibility to develop NAFLD was found to be related to polymorphisms of the gene for
phosphatidylethanolamine N-methyltransferase (PEMT) (Song et al., 2005) with loss of oestrogen
receptor binding (Resseguie et al., 2007, 2011), as well as to polymorphisms of other enzymes involved
in choline metabolism (CHDH and 5,10-methylenetetrahydrofolate dehydrogenase 1 (MTHFD1))
(Section 2.5 and Appendix C). Premenopausal women developed signs of choline deﬁciency less
commonly than postmenopausal women or men, possibly as a consequence of upregulation of hepatic
PEMT by oestrogen, leading to an increase in the endogenous synthesis of PC (Fischer et al., 2007;
Zeisel, 2007). PEMT is important for this endogenous synthesis of PC in case of insufﬁcient dietary choline
intake (Figure 2, Section 2.3.5). The amount of dietary choline to prevent organ damage or to maintain
normal organ function varies between people (Section 5.1.2). In addition, there is some evidence that
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the susceptibility to develop fatty liver with choline deﬁciency is inﬂuenced by the gastrointestinal
microbiome (Spencer et al., 2011) (Appendix D).
Zeisel (2012) reviewed the potential effects of choline deﬁciency on gene expression via epigenetic
marks and DNA integrity that could result in increased mutation rates and thereby increased risks of
certain cancers. An inﬂuence on the risk of breast cancer of single nucleotide polymorphisms (SNPs) of
several genes involved in choline metabolism and enhancing the requirement for dietary choline has
been observed in large epidemiological studies (Xu et al., 2008, 2009) (Appendix C and Section 2.5).
In subjects that received a choline diet providing < 50 mg choline/70-kg body weight (bw) per day,
fasting plasma concentration of total homocysteine (tHcy) signiﬁcantly increased among those with
clinical expression of choline deﬁciency compared with baseline (da Costa et al., 2005; Fischer et al.,
2007) (Section 5.1.1 and Appendix D). However, many factors besides dietary or endogenous choline
determine tHcy concentration in plasma (Section 2.4.3) (EFSA NDA Panel, 2014b, 2015).
2.2.2.2. Excess
The SCF did not consider choline when setting Tolerable Upper Intake Levels (ULs) for vitamins
and minerals. The US Institute of Medicine (IOM, 1998) deﬁned a UL for adults based on a study in
seven patients with Alzheimer’s dementia, where the oral administration of 7.5 g/day of choline (as
chloride) had a hypotensive effect accompanied by nausea and diarrhoea (Boyd et al., 1977). Similar
gastrointestinal effects and a ﬁshy body odour were observed in therapeutic studies with choline
(8–20 g/day) on individuals with tardive dyskinesia and Huntington’s disease (Growdon et al., 1977;
Gelenberg et al., 1979; Lawrence et al., 1980). The IOM considered 7.5 g/day of choline as the Lowest
Observed Adverse Effect Level (LOAEL), and after the application of an uncertainty factor of 2 and rounding,
set a UL of 3.5 g choline/day for adults. No UL was established for infants and ULs for children were derived
from the adult value by allometric scaling (exponent 0.75) according to reference body weights.
An association between an increased risk of cardiovascular diseases (CVD) and ‘higher intake’ of
choline, which possibly exceeds the intestinal absorption capacity for dietary free choline, has been
suggested by a metabolomic study (Wang et al., 2011), which investigated the relationship between
plasma choline and trimethylamine-N-oxide (TMAO) concentrations and risk of CVD. Non-absorbed
choline will become available to microbial degradation, predominantly to trimethylamine (TMA), which
is metabolised in the liver to TMAO (Sections 2.3.1 and 2.3.5.2.2). TMA has been found to promote
atherosclerosis in animals (Wang et al., 2011, 2014; Bennett et al., 2013; Tang et al., 2013). TMA has
also been suggested to be involved in depression, neurological symptoms, teratogenic effects in
humans as well as in the potential formation of the carcinogen N-nitrosodimethylamine (for a review,
see Bain et al. (2005)). These are indirect adverse effects of choline, depending both on a ‘high’
dietary amount and a speciﬁc gut microbiome (Wang et al., 2011). However, the dietary intake of
choline was not reported in these studies.
2.3. Physiology and metabolism
2.3.1. Intestinal absorption
Dietary free choline is quickly taken up by the enterocytes, mediated by the saturable organic cation
transporters (OCTs) (choline transporter-like protein 1 (CTL1) or solute carrier family 44 member 1
(SLC44A1); Section 2.3.3), which rely on facilitated diffusion governed by the choline concentration
gradient and the electrical potential across the membrane, then free choline is cleared from the plasma
within about 3 h (Zeisel et al., 1980; Jope et al., 1982). Dietary PC increases plasma free choline
concentration for 8–12 h, without a signiﬁcant rise in PC concentration in plasma (Zeisel et al., 1980; Jope
et al., 1982). PChol and GPC are rapidly absorbed and appear in plasma predominantly as free choline.
PC and GPC from the diet or secreted in the bile are hydrolysed by phospholipases (PLs) to liberate
choline (Zeisel and Blusztajn, 1994). Water-soluble choline compounds (PChol and GPC) can also enter
the portal circulation of the liver intact. Lipid-soluble compounds (PC and SPM) are either hydrolysed
by PLs or enter the lymph incorporated into chylomicrons.
Unabsorbed choline is catabolised by the intestinal microbiota to TMA (Sections 2.2.2.2 and
2.3.5.2.2). TMA is absorbed from the gastrointestinal tract and converted to TMAO in the liver.
The Panel notes that the amount of choline absorbed is restricted by the capacity of the transport
system via the saturable CTL1 or SLC44A1. The Panel notes that the available data do not allow
deﬁning the percentage of intestinal absorption of choline in humans.
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2.3.2. Transport in blood
Free choline is transported in the aqueous phase of plasma, whereas phosphorylated choline
compounds (i.e. PC, PChol, GPC, SPM) are associated with or are part of lipoproteins.
2.3.3. Distribution to tissues
As free choline is a charged hydrophilic cation, it needs transport mechanisms to cross biological
membranes. Three transport mechanisms are known (Fagone and Jackowski, 2013).
The ﬁrst is a sodium- and chloride-dependent high-afﬁnity (Km < 10 lM) (Okuda and Haga, 2000)
carrier-mediated saturable uptake system in presynaptic cholinergic nerve terminals, that is linked to
acetylcholine synthesis (Section 2.2.1). The transporter is the high-afﬁnity choline transporter (CHT;
solute carrier family 5 member 7 encoded by SLC5A7) that needs adenosine triphosphate (ATP)
hydrolysis. Disturbing the integrity of the cell membrane can reduce choline availability for
acetylcholine synthesis and diminish cholinergic transmission (Cuddy et al., 2014).
The second transport mechanism is a sodium-independent low-afﬁnity carrier-mediated saturable
mechanism (CTL1 or SLC44A1) in all tissues. This mechanism is energised by ATP hydrolysis, with an
average afﬁnity (Km) for choline of > 20–200 lM. It is present in enterocytes, hepatocytes, kidneys,
placental tissue, mitochondria and synaptosomes, and supplies choline for the synthesis of PC and SPM
as well as of betaine (Sections 2.2.1 and 2.3.5). This uptake is stereospeciﬁc and can be inhibited by
similar nitrogen-methyl compounds and by high concentrations of choline (Michel and Bakovic, 2012).
The third transport mechanism is a sodium-independent saturable uptake mechanism (a member of
the solute carrier 22 family), for choline to cross the blood–brain barrier and erythrocyte membranes
by facilitated diffusion. Its afﬁnity to choline is similar to the high-afﬁnity mechanism, but it is not
linked to acetylcholine synthesis (Cornford et al., 1980; Lockman and Allen, 2002).
Choline uptake by the mammary epithelium occurs by an energy-dependent saturable transport
system, but with higher maternal choline supply non-saturable transport can also occur. Choline is
metabolised within the mammary epithelium to PChol and other choline compounds or to a lesser
extent via degradation pathways (Fischer et al., 2010b; Davenport et al., 2015) (Sections 2.3.6,
2.4.1.2 and 5.1.3). The size of the efﬂux of choline compounds from the mammary epithelium occurs
via exocytosis or as a component of the milk fat globule (Davenport and Caudill, 2013).
Choline crosses the placenta via a speciﬁc transport system on both the maternal and fetal side of
the syncytiotrophoblast (Baumgartner et al., 2015), with an apparent small excess (about 4%)
preferential towards the fetal circulation, as demonstrated in perfusion studies with [3H]-choline
(Sweiry et al., 1986). Umbilical cord blood free choline concentration is about three times that of
maternal blood (Visentin et al., 2015) (Section 2.4.1.2).
2.3.4. Storage
Choline is stored in tissues either as membrane-bound phospholipids or as intracellular PC or GPC
(Zeisel and Blusztajn, 1994). Choline is stored in the brain as membrane-bound phospholipids, which
are hydrolysed by choline acetyltransferase to provide choline for acetylcholine synthesis
(Section 2.2.1). In most animal tissues, PC accounts for 95% of the total choline content, the
remaining 5% are choline, PChol, GPC, CDP-choline and acetylcholine (Li and Vance, 2008).
The content of choline and its metabolites in the body is balanced by two pathways of acquisition, i.e.
either diet and the CDP pathway, or the PEMT pathway (Sections 2.2.2.1 and 2.3.5, Figure 2), and two
pathways of depletion, i.e. either choline oxidation or the secretion of PC in the bile and, to a lesser
extent, by the intestinal mucosa (Li and Vance, 2008; Ehehalt et al., 2010) (Sections 2.3.5.2.1 and
2.3.6.2). Among bile phospholipids, 95% is PC, of which about 40% returns to the liver. Choline
imbalances can be compensated by adaptive increases in PEMTactivity, by recycling of choline, decreased
oxidation of choline, reabsorption of biliary PC, and by redistribution of tissue choline to maintain
homeostasis particularly in the brain and liver (Li et al., 2007; Li and Vance, 2008).
Regarding the choline content of adult tissues, data obtained with proton (hydrogen-1 [1H]) magnetic
resonance spectroscopy (MRS) are available. This method measures, besides choline as such, primarily
GPC and PChol, but also includes phosphatidylethanolamine (PE), glyceroPE, betaine, myo-inositol and
taurine; however, it does not include all choline lipids in membranes. The choline content of human
liver has been measured in vivo to be on average 8.6 mmol/kg or 894 mg/kg wet weight (range
3.8–17.6 mmol/kg; n = 44 including 24 women, mean age 46  17 years) using proton MRS (Ouwerkerk
et al., 2012). The choline content of quadriceps muscle was in the range 6.7–13 mmol/kg or
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697–1,352 mg/kg (n = 7 including 4 women, mean age 37.7 years, range 28–50 years) (Fayad et al.,
2010). The choline content in parietal white matter of the brain was (mean  SD) 1.73  0.24 mmol/L
or 180  25 mg/L (n = 20 including 11 women, mean age 29.4  7.4 years) (Mazzetti et al., 2013).
Regarding the fetus, infant and young child, phospholipids in the brain increase twofold in the cortex
(and threefold in the white matter) from the 10th week of gestation to the age of 2 years (Svennerholm
and Vanier, 1972). This study shows a relative continuous decrease in choline phosphoglycerides from
50% of total phospholipids in the cerebral cortex of the fetus to 45% in infants at term and 38% in children
at 2 years of age. In this study, SPM shows a continuous increase, from 3% of total phospholipids in the
cerebral cortex of the fetus to 5% in infants at term and 10% in children at 2 years of age.
Regarding the placenta, total lipid content is 14  1.0 mg/g dry tissue at term, and is rich in
phospholipids (about 80% of total lipids), of which 42.1  7.3% were choline glycerophospholipids
(Bayon et al., 1993; Bitsanis et al., 2005). The long-chain polyunsaturated fatty acids (LC-PUFAs),
arachidonic acid (ARA) and docosahexaenoic acid (DHA), are found in high proportion (about 40% of
the phospholipid fatty acids) in all phospholipid classes (Bayon et al., 1993; Bitsanis et al., 2005). The
placenta is one of the human organs most rich in free choline (14.6 mg/100 g wet weight) and this
concentration decreases by 50% in (pre)eclampsia (Mischel, 1956).
The Panel notes that no data are available on the total amount of choline in the human body. The
Panel also notes that there is a lack of data on the choline accretion in the fetus and placenta during
the duration of pregnancy.
2.3.5. Metabolism
2.3.5.1. Metabolism of choline and synthesis of phosphatidylcholine (PC)
Besides dietary intake, choline in the body can be generated de novo via the hepatic PEMT
pathway. Choline from both dietary and endogenous sources is incorporated into PC. PC is synthesised
in all cells from choline (Li and Vance, 2008).
The predominant pathway of PC synthesis in all cells is via the CDP-choline pathway. Free choline,
taken up into cells or generated by hydrolysis of choline compounds (Figure 2, right side), is
Left shows the endogenous synthesis of PC (PEMT pathway); right the synthesis of PC from (dietary)
choline (CDP pathway). BADH: betaine aldehyde dehydrogenase; BHMT: betaine homocysteine
methyltransferase; CCT: phosphocholine cytidyltransferase; CDP-choline, cytidine diphosphocholine;
CHK: choline kinase; CHDH: choline oxidase (or dehydrogenase); CPT: CDP-choline diacylglycerol
choline phosphotransferase; DMG: dimethylglycine; Hcy: homocysteine; methyl-THF: methyltetrahy-
drofolate; MS: methionine synthase; PChol: phosphocholine; PE: phosphatidylethanolamine; PEMT:
phosphatidylethanolamine N-methyltransferase; PC: phosphatidylcholine; SAH: S-adenosylhomocysteine;
SAH-H: S-adenosylhomocysteine hydrolase; SAM: S-adenosylmethionine; THF: tetrahydrofolate.
Figure 2: PC synthesis and choline metabolism and its involvement in folate-dependent one-carbon
metabolism
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phosphorylated by choline kinase (CHK) to PChol or oxidised to betaine in some cell types like liver and
kidney. PChol reacts with cytidine triphosphate (CTP) to form cytidine 5-diphosphate choline (CDP-
choline) by phosphocholine cytidyltransferase (CCT). CDP-choline is esteriﬁed with diacylglycerol by
choline phosphotransferase (CPT) or the choline/ethanolaminephosphotransferase (CEPT) to form PC
(Li and Vance, 2008).
The other pathway of PC synthesis in the human body de novo (PEMT pathway) starts from
3-phosphoglycerate, which receives two acyl groups from acyl-coenzyme A and is converted to a
phosphatidate (not shown in Figure 2). Phosphatidate can react with CTP to form cytidine
diphosphate-diacylglycerol, whose hydroxyl group can react with serine to form phosphatidylserine
that is decarboxylated to PE. PE can then be methylated in the liver to synthesise PC (Figure 2, left
side). This reaction is catalysed by PEMT, which is dependent on SAM, and consumes three molecules
of SAM, while releasing three molecules of S-adenosylhomocysteine (SAH) per molecule of formed PC.
Quantitatively, this appears to be the most important SAM-dependent transmethylation reaction and
source of Hcy in mammals (Stead et al., 2006). The PEMT pathway is mostly active in the liver, but
some low activity has been described in other tissues, e.g. in adrenal medulla, mammary gland and
adipose tissue at about 0.1% of the hepatic activity (Vance, 2014).
The PEMT pathway accounts for 30% of hepatic PC synthesis in rodents, while 70% are produced
from choline via the CDP-choline pathway (Reo et al., 2002; Li and Vance, 2008). The gene for PEMT has
multiple oestrogen-responsive elements and its transcription is enhanced by oestradiol in vitro.
Oestrogen enhanced activity of PEMT can provide for the increased demand for choline during pregnancy
when oestrogen concentrations are high (Resseguie et al., 2007) (Sections 2.2.2.1 and 5.1.3).
PC derived via the two different pathways apparently enters separate pools. PC formed in the
hepatic PEMT pathway differs from that generated via the CDP-choline pathway, in that it contains
primarily LC-PUFAs like DHA and ARA instead of medium-chain, mono- and bi-unsaturated and
saturated fatty acids. This has been demonstrated in studies with deuterated choline and ethanolamine
in rat and mouse liver, and in mice and humans after parenteral administration of methyl-D9-choline
4
(DeLong et al., 1999; Pynn et al., 2011) and using multiple isotopomer distribution analysis (MIDA)
(Pynn et al., 2011). In addition, in 21 healthy non-pregnant women randomised to consume for
12 weeks either 480 or 930 mg choline/day (about 20% of which was provided as methyl-D9-choline
for the last 6 weeks), Yan et al. (2013) demonstrated that the higher choline intake (930 mg/day)
favours the use of the PEMT pathway (relative to CDP-choline pathway), and yielded a signiﬁcantly
higher isotope enrichment in plasma PC-DHA (West et al., 2013) (Section 5.1.3).
The ratio of PC-DHA to total PC in plasma is considered a surrogate measure for hepatic PEMT
activity (3% of total plasma PC is PC-DHA). It is signiﬁcantly greater (p < 0.01) in premenopausal
women than in men or in postmenopausal women. It is signiﬁcantly lower (p < 0.05) in
premenopausal women homozygous for the loss-of-function rs12325817 SNP of the PEMT gene than in
women with the wild-type of PEMT. This has been conﬁrmed by measuring PEMT activity in liver
biopsies together with the PC-DHA concentration (da Costa et al., 2011) (Appendix D).
The Panel notes that the PC required by the body can be derived from dietary choline and from
endogenous synthesis, but is distributed into different pools and carries different fatty acids. The PC
formed in the PEMT pathway contains substantial amounts of LC-PUFAs, like DHA and ARA, while the
PC formed in the CDP-choline pathway does not. The PEMT pathway is mostly active in the liver, but
some low activity has been described in, e.g. in adrenal medulla, mammary gland and adipose tissue.
The CDP-choline pathway is present in all cells of the body. Both can be stimulated by dietary choline.
Moreover, the PEMT pathway is sensitive to the presence of oestrogens.
2.3.5.2. Degradation
Catabolism of phospholipids is initiated by PLs hydrolysing their respective bonds: i.e. PLA1 and
PLA2 hydrolyse fatty-acyl bonds (e.g. PC to lysophosphatidylcholine (lyso-PC)), PLC glycerophosphate
bonds, and PLD choline phosphate ester bonds. Further, lysoPL degrades lysophosphatidylcholine,
which is subsequently converted to GPC and further hydrolysed to choline by a phosphodiesterase
(Lockman and Allen, 2002).
4 Methyl-D9-choline, with fully deuterated methyl groups, can either be converted via the CDP-choline pathway to D9-PC or by
oxidation to D9-betaine that will transfer D3-methyl groups to homocysteine via BHMT, forming D3-methionine and D6-DMG.
D3-methionine can transfer deuterated methyl groups to PE via PEMT, forming predominantly D3-PC and D6-PC. By estimating
the enrichment of the different metabolites and the ratios of deuterated isotopomers, an assessment of the metabolic ﬂuxes is
possible (Pynn et al., 2011).
Dietary Reference Values for choline
www.efsa.europa.eu/efsajournal 13 EFSA Journal 2016;14(8):4484
2.3.5.2.1. Choline oxidation to betaine
Oxidation of choline in the liver and kidney produces, in a two-step enzymatic reaction, ﬁrst betaine
aldehyde by mitochondrial CHDH, and then betaine by mitochondrial or cytoplasmic BADH (Lin and
Wu, 1986) (Figure 2). Mitochondrial betaine synthesis from choline is controlled by choline transport
across the mitochondrial membrane (O’Donoghue et al., 2009). The formation of betaine links choline
to the folate-dependent one-carbon metabolism, because betaine is the methyl-group donor in the
BHMT reaction (Sections 2.2.1, 2.3.6.1.2 and 2.3.7). This reaction converts Hcy in the liver and kidney
to methionine and releases dimethylglycine (DMG), which is converted into sarcosine and methylene-
tetrahydrofolate with tetrahydrofolate (THF) as methyl-group acceptor. The resultant sarcosine can be
degraded into glycine or be excreted in the urine, while methylene-THF can be reduced to methyl-THF
by methylene-THF reductase (MTHFR) (Ueland et al., 2005) (Section 2.5).
2.3.5.2.2. Microbial choline degradation to trimethylamine (TMA)
Non-absorbed choline is one of the precursors of TMA produced in the gut by anaerobic symbiotic
microbes (Zhang et al., 1999; Craciun and Balskus, 2012) (Section 2.2.2.2). TMA is efﬁciently absorbed
from the gastrointestinal tract (Al-Waiz et al., 1987), and then converted in the liver to TMAO by the
ﬂavin-containing monooxygenase isoform 3 enzyme (FMO3) (Lang et al., 1998). Both TMA and TMAO
are eliminated in the urine (urinary total TMA i.e. TTMA = TMA plus TMAO).
TMA has an unpleasant ﬁshy odour and can result in a corresponding ﬁshy body odour when either
choline intake is ‘high’ (Section 2.2.2.2), the intestinal microbiota is disturbed or the subjects suffer
from autosomal-recessive trimethylaminuria due to defects in FMO3 (Mitchell and Smith, 2001; Zeisel
et al., 2003).
On ‘normal’ diets, only milligram amounts of TMA were excreted in the urine of healthy subjects
and subjects with liver cirrhosis, but when single choline doses of 2–8 g as bicarbonate were given on
separate occasions, about 69% of choline nitrogen was excreted in the urine as TMA nitrogen (De la
Huerga and Popper, 1951).
In a study in six healthy males, measuring the conversion of single oral doses of 15 mmol of
choline or PC (i.e. 2.1. and 11.65 g, respectively, given on separate occasions at least 2 weeks apart)
into urinary TTMA, about 63% of choline appeared as urinary TTMA within 3 days after ingestion
(Zhang et al., 1999). In this study, PC did not lead to similar increases in urinary TTMA concentration
(0.5–2% of the administered dose).
However, a double-blind randomised controlled trial (RCT) in six healthy volunteers (four women),
consuming single increasing amounts of PC separated by 2–4 weeks (119 up to 714 mg/day of
choline, mainly as PC, in the form of egg yolk(s)) in addition to a low-choline diet,5 demonstrated that
an intake of increasing amounts of PC resulted in a rise in TMAO concentrations in both plasma and
urine (Miller et al., 2014). TMAO concentration in plasma increased in ﬁve of six subjects after egg
ingestion, with a peak after 6–8 h; however, there was great interindividual variability. TMAO
concentration in urine in the 24 h after egg yolk ingestion increased in proportion to the amount of PC
ingested (11–15% of the total ingested choline). The authors also found differences in the proﬁle of
the faecal microbiome and in the gene for the FMO3 enzyme (the SNP FMO3 G566A, rs2266782 is
associated with a 25% reduction in the enzyme activity) between the study participants. This may
explain the variable responses of plasma and urinary TMAO concentrations to PC intake.
The Panel notes a relationship between dietary choline, microbial metabolism of choline to TMA,
hepatic TMAO production and urinary TTMA excretion. The Panel notes as well an inﬂuence of other
dietary, genetic and environmental factors on TMA production. The Panel concludes that a dose–
response relationship between dietary choline and hepatic TTMA production cannot be established.
2.3.6. Elimination
2.3.6.1. Urine
The kidneys accumulate choline via the sodium-independent low-afﬁnity carrier-mediated saturable
mechanism described in Section 2.3.3.
5 11 mg choline/1,000 kcal per day, i.e. about 2.6 mg choline/MJ per day.
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2.3.6.1.1. Choline and trimethylamine-N-oxide (TMAO)
Excretion of choline in the urine is low in relation to usual dietary intakes. De la Huerga and Popper
(1951) (Section 2.3.5.2.2) determined the excretion of choline and TMA in the urine in four healthy
adult subjects after single oral doses of 2–8 g of choline (as choline bicarbonate). The authors
detected no or negligible choline in urine at baseline and not more than 0.3% of the administered
dose thereafter. Within 24 h, two-thirds of the administered dose was excreted as TMA and TMAO,
which suggests that unabsorbed choline was metabolised by the intestinal microbiota.
In pregnant and non-pregnant women (consuming either 480 or 930 mg of choline/day for
12 weeks), the (geometric) mean of the excretion of choline in the urine throughout the 12-week
study was 10.7 (95% conﬁdence interval (CI): 8.1–14.1) and 3.2 (95% CI: 2.3–4.4) mg/day,
respectively (p ≤ 0.001), and did not change signiﬁcantly with choline intake (Yan et al., 2012)
(Sections 2.3.6.1.2, 2.4.1.2, 5.1.3 and 6.4). In lactating and non-lactating women (the latter from the
study by Yan et al. (2012)), mean excretion of choline in the urine throughout the study
(10–12 weeks) did not differ (Davenport et al., 2015) (Sections 2.3.3, 2.3.6.1.2, 2.3.6.3, 2.4.1.2 and
5.1.3).
2.3.6.1.2. Betaine and dimethylglycine (DMG)
Betaine in the urine originates either from the diet or is formed in the kidney (and liver) via CHDH
and BADH from choline. In this reaction, betaine is a methyl-group donor for Hcy remethylation
(Figure 2 and Sections 2.2.2.1 and 2.3.5.2.1). BHMT demonstrates saturation kinetics, its activity
increases in rat liver when the diet is low in methionine but contains choline or betaine (Park and
Garrow, 1999) and its activity is inhibited by DMG, which is the product of BHMT activity. Moreover,
oxidative demethylation of DMG to sarcosine is the rate-limiting step in betaine metabolism. Betaine
normally accumulates in the kidney medulla, where its release into the urine is controlled by
intracellular tonicity.
While the betaine plasma concentration remains almost stable on a habitual diet, it increases
rapidly about 30-fold following one oral dose of about 50 mg betaine/kg bw in 12 healthy males and
has an elimination half-life of around 14 h (Schwahn et al., 2003a). In this study, on average, 4% of
the ingested dose was excreted as betaine in the 24-h urine; the renal clearance6 was in the range of
0.4–13.9 mL/h per kg bw and about 5% of the apparent total plasma clearance. Betaine is freely
ﬁltered in the kidney, but normally almost completely reabsorbed in the proximal tubule (Lever et al.,
2007).
In a randomised cross-over study on eight healthy males consuming ﬁve different intervention
meals, including one high-choline meal (564 mg) or a single dose of choline supplement (500 mg, as
choline chloride), compared to a low-choline meal (< 1 mg choline), urinary betaine excretion was not
signiﬁcantly different between groups (Atkinson et al., 2008). In contrast, in this study, urinary DMG
excretion peaked at 4–6 h (p < 0.005 compared to control), but was still higher than baseline
(p < 0.05) 24 h after the high-choline meal.
In women consuming either 480 or 930 mg of choline/day for 12 weeks (Yan et al., 2012), the
(geometric) mean of the excretion of betaine in the urine throughout the 12-week study was 12.9
(95% CI: 10.0–16.6) mg/day in pregnant women and 8.1 (95% CI: 6.1–10.8) mg/day in non-pregnant
women (p ≤ 0.05) (Sections 2.3.6.1.1, 2.4.1.2, 5.1.3 and 6.4). Lactating women had a lower excretion
of choline metabolites (betaine: 3 mg/day, p = 0.001; DMG: 2.3 mg/day, p < 0.001) in the urine
throughout the study period compared to non-lactating control women (Davenport et al., 2015)
(Sections 2.3.6.1.1, 2.3.6.3, 2.4.1.2 and 5.1.3).
Infants excrete high amounts of betaine in their urine, up to 1.5 mmol/mmol creatinine (1.55 g/g
creatinine) during the ﬁrst year of life, with a maximum at the age of 2–3 months and a decrease to
0.2 mmol/mmol creatinine at 1 year (Holmes et al., 1996). During the ﬁrst 10 days of life, a urinary
excretion of betaine of 27.4  2.8 lmol/kg bw per day (3.2  0.3 mg/kg per day; mean  SEM) was
reported in 27 infants. At that age, no dietary source of betaine is available (Holmes et al., 1996), besides
human milk with its low concentration of betaine (360–515 lg/L) (Davenport et al., 2015). In the
newborn period, urinary excretion of betaine may be higher than choline intake (Davies et al., 1992).
6 Deﬁned as the ratio of 24 h urinary excretion (mmol/kg bw) to the respective area under the curve (in mmol/L per hour).
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2.3.6.1.3. Conclusion on urinary excretion
The Panel notes that choline excretion in the urine is low in relation to usual dietary intakes (and
0.3% of the administered dose of 2–8 g choline). A study showed that pregnant women have higher
urinary excretion of choline and betaine than non-pregnant women. The Panel notes that excretion of
betaine in urine may be of dietary origin or produced from choline. The rise in urinary DMG
concentration, the second product of BHMT activity, after a choline supplement or a high-choline meal,
suggests that choline-derived betaine is primarily used for Hcy remethylation in the liver (rather than
fulﬁlling the other functions of betaine in the body).
2.3.6.2. Faeces
Hepatic PC, synthesised either from dietary choline via the CDP-choline pathway or via the PEMT
pathway (Figure 2), is used for secretion of VLDL or formation of high-density lipoproteins (HDL), or
secretion into the bile. In mice, PC secretion into the bile was equivalent to the entire hepatic PC pool,
of which 95% is reabsorbed (Li and Vance, 2008). In addition, PC is secreted by the intestinal mucosa,
according to data in animals and patients (Ehehalt et al., 2010).
No human data are available on faecal excretion of choline or choline compounds in relation to
dietary choline intake. Depending on the composition of the gut microbiome, non-absorbed choline in
the gut can be converted to TMA (Sections 2.2.2.2 and 2.3.5.2.2).
2.3.6.3. Breast milk
Choline is found in breast milk predominantly as PChol and GPC, together with free choline, PC,
SPM. Its concentration changes during the progress of lactation, and is inﬂuenced by maternal diet
(Fischer et al., 2010b; Davenport et al., 2015). Apart from choline and choline containing compounds,
breast milk also contains betaine (Davenport et al., 2015).
In an RCT in 103 pregnant (then lactating) women (94 completers), Fischer et al. (2010b)
(Sections 2.3.3, 2.4.1.2, 2.5.1, 5.1.3 and 5.2.5) investigated the response of maternal plasma and
breast milk choline concentrations to a PC supplement (750 mg/day choline, n = 48, from the 18th
gestational week to 90 days post partum), compared to placebo (n = 46). The supplement was
consumed in addition to a mean dietary choline intake of about 350 mg/day (measured by a three-day
food record at 45 days post partum). Breast milk (and maternal plasma) concentrations were
measured at 45 days post partum. There was a signiﬁcant linear correlation between total choline
intake (sum of all choline compounds from foods and supplements, range about 150 mg/day to
> 750 mg/day) and breast milk concentrations of PChol, PC, free choline and betaine (R2 = 0.16 and
p = 0.0001, R2 = 0.07 and p = 0.02, R2 = 0.08 and p = 0.001, R2 = 0.13 and p = 0.0003,
respectively), when all subjects were taken into account. Mean ( SE) breast milk concentrations of
PChol (722  39 vs 553  27 lmol/L) and free choline (106  10 vs 83  8 lmol/L) were
signiﬁcantly higher (p < 0.001) in the supplemented group than in the placebo group, whereas PC,
GPC and SPM were not signiﬁcantly different.
In a controlled feeding study, Davenport et al. (2015) (Sections 2.3.3, 2.3.6.1, 2.4.1.2 and 5.1.3)
investigated the response of breast milk choline concentration to different choline intakes. In this
study, lactating (n = 28, 5 weeks post partum) and non-pregnant non-lactating (n = 21, control)
women were randomised to consume 480 mg/day (15 lactating women and 10 controls) or 930 mg
choline/day (13 lactating women and 10 controls), from food and supplements,7 for 10 (lactating
women) or 12 weeks (control women). Lactating women consuming 930 mg/day choline had a
signiﬁcantly higher concentration of total choline in breast milk (sum of all choline compounds) at the
end of the study compared to those consuming 480 mg/day (mean  SD: 1,200  60 vs
1,000  50 lmol/L, p = 0.041). They also had higher concentrations of PChol (392  26 vs
285  24 lmol/L, p = 0.008) and GPC (471  36 vs 346  33 lmol/L, p = 0.031), but their free
choline concentration in breast milk did not differ (148  13 vs 158  12 lmol/L). During the last
4–6 weeks, 20% of the total intake of choline was provided as deuterium labelled choline (methyl-D9-
choline). Women consuming the higher choline intake (930 mg/day) during lactation had in their
breast milk, at the end of the study, a signiﬁcantly higher enrichment of the metabolites generated
endogenously via the hepatic PEMT pathway, but not of the metabolites generated from intact
exogenous choline via the CDP-choline pathway (see pathways in Figure 2, Section 2.3.5). The
7 Diet provided an average of 380 mg/day of choline, and supplemental choline was 100 or 550 mg/day.
Dietary Reference Values for choline
www.efsa.europa.eu/efsajournal 16 EFSA Journal 2016;14(8):4484
Panel notes that the higher choline intake during lactation (930 mg/day compared to 480 mg/day)
signiﬁcantly increased the concentration of total choline in breast milk, and increased the supply of
PEMT-derived choline metabolites in breast milk.
The content of PC and SPM in breast milk was reported to remain constant from day zero to 85 of
lactation, while the content of GPC, PChol and, to a lesser extent, free choline, in breast milk increased
signiﬁcantly after the ﬁrst week after birth (Zeisel et al., 1986), but only free choline content decreased
signiﬁcantly with time.
A search of the literature published after January 2000 was performed as preparatory work to this
assessment, in order to identify breast milk composition data for choline (LASER Analytica, 2014). This
search was completed with two additional papers (Holmes-McNary et al., 1996; Davenport et al.,
2015). Appendix A reports data from six studies (Holmes-McNary et al., 1996; Holmes et al., 2000;
Ilcol et al., 2005; Fischer et al., 2010b; Ozarda et al., 2014; Davenport et al., 2015) conducted in the
UK, Turkey and the USA, on the mean/median free and total choline concentrations of human milk
from healthy lactating mothers. Either the infants were full-term (Holmes-McNary et al., 1996; Ozarda
et al., 2014), or there was a mixed population of full-term and preterm infants or it was unclear
whether the infants were born at term or not.
Stages of lactation varied between birth and 180 days post partum. Mean maternal choline intake
was not reported in four studies (Holmes-McNary et al., 1996; Holmes et al., 2000; Ilcol et al., 2005;
Ozarda et al., 2014), while one study compared choline supplemented versus non-supplemented
women (Fischer et al., 2010b) and the other compared two doses of choline supplementation
(Davenport et al., 2015). Three studies (Ilcol et al., 2005; Fischer et al., 2010b; Davenport et al.,
2015) reported information on maternal plasma choline concentration (considered by the authors as
an indication of maternal status). The mean/median concentration of total choline (sum of
compounds) in mature milk ranged from 120 to 160 mg/L (see Appendix A).
Based on the two studies on full-term fully breast-fed infants (Holmes-McNary et al., 1996; Ozarda
et al., 2014) in the USA and Turkey (n = 70 women in total), an average total choline concentration
(free choline and choline compounds) of about 145 mg/L in mature breast milk can be calculated.
Assuming a mean milk transfer of 0.8 L/day during the ﬁrst 6 months of lactation in exclusively
breastfeeding women (Butte et al., 2002; FAO/WHO/UNU, 2004; EFSA NDA Panel, 2009), the estimated
secretion of choline into milk during lactation would be 116 mg/day, rounded to 120 mg/day.
The Panel notes that breast milk mainly contains PChol and GPC, besides free choline, PC and SPM,
in concentrations depending on the progress of lactation and maternal diet/supplementation. The
Panel also notes that increased maternal choline intake enhances the concentration of total choline in
breast milk and increases the supply of PEMT-derived choline metabolites in breast milk. The
Panel considers that secretion of choline into breast milk during the ﬁrst 6 months of exclusive
breastfeeding is about 120 mg/day.
2.3.7. Interaction with other nutrients: folate
Folate and choline are both involved in the remethylation of Hcy to methionine, the ﬁrst via
5-methyl-THF, the latter via betaine. The interrelationship between folate and choline metabolism has
been demonstrated in animal studies (Varela-Moreiras et al., 1992; Kim et al., 1994) (Section 2.3.5.2.1).
In the ﬁrst case, Hcy is methylated to methionine by the ubiquitous methionine synthase (MS, Figure 2),
which requires methyl-THF as methyl-group donor and cobalamin as cofactor (Ueland et al., 2005). In
the second case, Hcy is methylated to methionine by BHMT (Figure 2), which requires betaine as methyl-
group donor. Choline insufﬁciency, with consequently low betaine formation, increases the requirement
for methyl-THF for the remethylation of Hcy and, therefore, the requirement for dietary folate. Vice
versa, in folate depletion, methyl groups from choline and betaine are increasingly used for Hcy
remethylation, thereby increasing the requirement for choline. Methyl-THF and choline/betaine can be
considered as partially exchangeable sources of methyl groups (Kim et al., 1994).
Jacob et al. (1999) investigated the effect of folate depletion and repletion on choline status and
the in vivo methylation capacity in humans residing in metabolic units. Following a baseline period of
6–9 days on a diet sufﬁcient in energy and all nutrients including folate (440 lg/day), 11 healthy men
(aged 33–46 years) and 10 healthy women (aged 49–63 years) consumed, for 4–5 weeks, a low folate
(average of 25 lg/day and 56 lg/day for men and women, respectively) and low choline diet (average
of 238 mg/day and 147 mg/day for men and women, respectively). Two to six weeks of folate
repletion followed (440 and 516 lg folate/day for men and women, respectively, partially supplied as
folic acid) without change in the choline intake. Variation in the methionine content of the diet in men
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(400 mg or 1,400 mg/day in the ﬁrst half of the study period with cross-over thereafter) had no effect
on the outcomes (this was not investigated in women). No functional deﬁciencies of organs were noted
in any subject. Methylation capacity, as assessed by the urinary excretion of creatinine and of
methylated nicotinamide breakdown products after ingestion of 1 g of nicotinamide, was not
diminished. At the end of the folate depletion phase, plasma free choline (and folate) concentrations
were signiﬁcantly lower in both men and women compared with baseline, and plasma tHcy
concentration was signiﬁcantly higher while plasma PC concentration was decreased in men compared
to baseline (PC concentration was not investigated in women). At the end of the folate repletion phase,
plasma choline concentrations increased signiﬁcantly in both sexes compared to the folate depletion
phase (p < 0.05), in women to even higher values than at baseline (p < 0.05), with no signiﬁcant
change in plasma tHcy concentration compared to the folate depletion phase. No changes in choline,
folate and SAM concentrations in red blood cells were noted throughout the study. The Panel notes
that, in this study, an adequate folate intake maintained plasma choline concentration despite a low
choline intake of about 150–250 mg/day on average, while plasma free choline and PC concentrations
decreased and tHcy concentration increased when both folate and choline intakes were low.
In 43 premenopausal Mexican-American women, folate intake was restricted for 7 weeks to 135 lg
dietary folate equivalent (DFE) per day, followed by 7 weeks of randomisation to either 400 or 800 lg
DFE/day, while choline intake was kept constant at 349 mg/day (including 250 mg/day of a choline
supplement) (Abratte et al., 2008). In this study, plasma PC concentration decreased during dietary
folate restriction compared with baseline (p = 0.001), presumably due to the unfulﬁlled demand of
folate-derived one-carbon units for PC synthesis. Plasma PC concentration increased again after
administration of 800 lg DFE/day (p = 0.03) (but not signiﬁcantly with 400 lg DFE/day). The
Panel notes that, in this study, folate intake was shown to inﬂuence plasma PC concentration.
Changes in the activity of enzymes involved in folate and choline metabolism, due to
polymorphisms of genes for enzymes of this metabolism, can be expected to have an impact on the
status of folate and choline. An example is the C677T genotype of the MTHFR (Sections 2.3.5.2.1 and
2.5), which has a strong inﬂuence on folate status (Abratte et al., 2008).
Ivanov et al. (2009) examined the potential inﬂuence of polymorphisms of two genes involved in
choline metabolism (MTHFD1 rs2236225 and PEMT rs12325817 and rs7946) (Section 2.5. and
Appendix C) on plasma PC and tHcy concentrations in the presence of folate restriction in the same
Mexican-American women studied by Abratte et al. (2008). These polymorphisms are functional in that
they impair the activity of the two enzymes (PEMT and MTHFD1) and thereby possibly increase choline
requirement and compromise the production of methyl-THF. The PEMT and MTHFD1 polymorphisms
did not modify the small negative response of plasma PC concentration to folate restriction, except in
case of homozygosity for PEMT rs1232587 that attenuated the decline in plasma PC concentration.
Homozygosity for PEMT rs7946 and MTHFDH1 rs2236225 SNPs was associated with a greater increase
(p < 0.001) in plasma tHcy concentration during folate restriction than in subjects homozygous for the
wild-type.
The Panel notes that, in the available studies, low folate intake had a negative impact on plasma
PC concentration in the presence of ‘adequate’ choline intake, and that the impact of SNPs of genes of
some enzymes involved in metabolic pathways of choline may result in increased tHcy concentrations
in plasma during folate restriction. These changes are not predictable due to compensatory changes in
other parts of those pathways. The Panel, moreover, notes the small number of subjects investigated
and stratiﬁed for genetic polymorphisms that limits the generalisation of these studies.
2.4. Biomarkers
2.4.1. Plasma/serum concentration of free choline and choline-compounds and
metabolites
2.4.1.1. Adults
Fasting plasma free choline concentrations usually range between 7 and 20 lmol/L, with most
subjects having a concentration of 10 lmol/L (IOM, 1998). Plasma choline concentrations are
regulated, however, some variability in plasma concentrations occurs with changes in choline intake.
Choline-deﬁcient diets, as applied in depletion/repletion studies (Section 5.1.2) and consumed over
weeks, can reduce plasma free choline concentration by approximately 30%, and ingestion of choline-
rich foods (e.g. ≥ 500 mg/day) can increase plasma free choline concentrations beyond 20 lmol/L
(Zeisel et al., 1991) (Appendix D). Plasma free choline concentration was found not to decrease
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beyond 50% of the initial normal value even after 1 week of total fasting, presumably because of
release of choline from membrane phospholipids (Savendahl et al., 1997).
Fasting plasma PC concentration varied between adults (1.5–2.5 mmol/L) and decreased by 30%
after 3 weeks on a low choline diet, while erythrocyte PC concentration decreased by 10% (Zeisel
et al., 1991).
2.4.1.2. Pregnancy and lactation
During pregnancy, serum free and phospholipid-bound choline concentrations increase compared
with non-pregnant women (Ozarda Ilcol et al., 2002).
The controlled feeding study by Yan et al. (2012) (Sections 2.3.6.1, 5.1.3 and 6.4) compared the
effects of two doses of choline supplementation (480 or 930 mg of choline/day from food and
supplements) in healthy pregnant (recruited at 27 weeks gestation) and non-pregnant women. In this
study, pregnant women had similar mean plasma free choline concentration as non-pregnant women
at recruitment, but signiﬁcantly higher concentration (by 30%) than non-pregnant women throughout
the 12-week study (geometric means, (95% CI): 8.2 (7.6–8.7) vs 6.3 (5.6–6.9) lmol/L, respectively,
p < 0.001). Pregnant women had lower mean plasma concentrations of the three methyl-group donors
(betaine, DMG, sarcosine) as well as methionine and Hcy at recruitment, and this persisted throughout
the study (lower by 13–55%, p < 0.001). The lower circulating concentrations of choline-derived
methyl-group donors in pregnant women, than in non-pregnant women, throughout the study, were
possibly a consequence of the greater use of these molecules in both maternal and fetal
compartments. Pregnant women consuming 930 mg choline/day had a 13% higher mean plasma
concentration of free choline than those consuming 480 mg choline/day (p = 0.021).
In a prospective observational study, choline intake of 154 pregnant women, estimated by a food
frequency questionnaire (FFQ), was weakly correlated to their natural log-transformed plasma
concentration of free choline at 16 and 36 weeks of gestation (16 weeks: r = 0.20, p = 0.013, range
of intake read on ﬁgure: 150–700 mg/day) (Wu et al., 2012).
In a prospective cohort study on 368 Canadian pregnant women recruited at 12–16 weeks of
gestation, Visentin et al. (2015) investigated the relationship between maternal choline intake and
concentrations of choline and its metabolites in maternal and umbilical cord plasma. Mean maternal
choline intake (total of all compounds), as estimated by a semiquantitative FFQ, was 306  127 and
302  122 mg/day in early (0–16 weeks) and late (23–37 weeks) pregnancy, respectively. Mean
maternal plasma free choline (95% CI) was 7.2 (7.1–7.4) lmol/L. The mean concentrations of free
choline, DMG and TMAO in maternal plasma increased signiﬁcantly (p ≤ 0.005) between recruitment in
pregnancy and delivery by 49%, 17% and 13%, respectively, whereas that of betaine decreased by
21% (p ≤ 0.005). Maternal dietary intake (total or free) was not associated with these maternal
plasma concentrations. The mean concentrations of free choline, betaine and DMG in cord plasma
were 3.2, 2.0 and 1.3 times the concentrations in maternal plasma at delivery, whereas the mean
concentration of TMAO in cord plasma was lower by 12%. Maternal dietary choline intake (or fetal
genetic variants in genes involved in choline metabolism,8 Appendix C) was not associated with cord
plasma concentrations of free choline and its metabolites. In contrast, maternal plasma concentrations
of betaine, DMG and TMAO at delivery strongly inﬂuenced umbilical cord plasma concentrations (r2
between 0.19 and 0.51, all p < 0.0001, after adjustment for potential confounders). There was only a
weak correlation between the concentration of free choline in maternal and umbilical cord plasma
(r2 = 0.12, p = 0.06).
Results are indicative of an active transport of choline from the mother to placental tissue
(Section 2.3.3) and/or an uptake and metabolism of choline by the fetus reﬂecting a demand of the
fetus for choline and methyl-group donors.
In lactating women, serum free and phospholipid-bound choline concentrations were signiﬁcantly
higher than in non-lactating women (p < 0.05), and gradually decrease until 180 days after the birth
of the child (Ilcol et al., 2005).
In the lactating women of the RCT by Fischer et al. (2010b) (Sections 2.3.3, 2.3.6.3, 2.5.1, 5.1.3
and 5.2.5), there was a signiﬁcant correlation between total choline intake (from foods and
supplements) and maternal plasma concentration of free choline (R2 of 0.15 in the supplemented
group, and 0.55 in all subjects combined, p = 0.03 and p = 0.0001, respectively). Choline
supplementation increased mean maternal plasma concentration of free choline compared to placebo
(mean  SE: 13.7  0.6 vs 7.7  0.3 nmol/mL at 45 days post partum, p < 0.001).
8 Ten SNPs in seven candidate genes.
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In addition, in the controlled feeding study by Davenport et al. (2015) (Sections 2.3.3, 2.3.6 and
5.1.3), lactating women showed higher (+ 27%, p < 0.001) plasma free choline concentrations than
non-pregnant non-lactating women throughout the study period. Lactating women who consumed
930 mg/day choline had signiﬁcantly higher plasma free choline concentration (+ 16%, p = 0.012)
compared to those consuming 480 mg/day.
2.4.1.3. Infants
In newborns, serum free choline concentrations were signiﬁcantly higher (greater than twice
maternal values) and phospholipid-bound choline concentrations were signiﬁcantly lower (by about
40%) than in their mothers (Holmes et al., 2000). Phospholipid-bound choline plasma concentrations
in the infants rose by 40% starting from day 5 to day 15 after birth to reach adult levels by the age of
about 10 years. Plasma free choline concentration of newborns remained high for 2 weeks after birth,
was still slightly higher than adult levels at the age of 2 years and remained stable at around 10 lmol/
L at the age 3–12 years. This high newborn’s plasma concentration possibly reﬂects the increase in
choline in breast milk in the second week of life (Section 2.3.6.3). There was no correlation between
maternal and newborn plasma phospholipid-bound choline (Buchman et al., 2001; Ilcol et al., 2005).
2.4.1.4. Conclusion on plasma/serum concentration of choline and choline-compounds
and metabolites
The Panel notes age-related changes in choline concentrations in plasma/serum, with higher values
in infants and young children than in adults. Plasma choline concentration may increase when intake is
increased, and decreases by up to 50% when dietary intake is severely restricted (Zeisel et al., 1991;
Savendahl et al., 1997).
The Panel also notes that pregnancy and lactation are associated with higher free choline
concentrations in plasma than in the non-pregnant non-lactating state, and that choline
supplementation increases maternal plasma concentration of free choline in pregnancy or lactation.
However, the Panel considers that the maternal intake of choline cannot be deduced from the choline
concentration in maternal plasma during early and late pregnancy or lactation, nor from the choline
concentration in venous umbilical cord plasma.
No dose–response relationship between choline intake and plasma concentration of free choline, or
of PC, betaine, DMG or TMAO, or erythrocyte PC, can be deduced from the available data. Therefore,
the Panel considers that plasma concentrations of choline and choline compounds or metabolites
cannot be used for setting DRVs for dietary choline.
2.4.2. Total trimethylamine (TTMA) hepatic production
The Panel concludes that TTMA hepatic production and excretion in urine are not predictably
related to dietary choline intake and cannot be used for setting DRVs for dietary choline
(Section 2.3.5.2.2).
2.4.3. Plasma total homocysteine
Appendix B compiles the results of six studies on adults (19–82 years of age) investigating the
inﬂuence of choline intake on plasma tHcy concentrations. Three studies were RCTs (Olthof et al., 2005;
Atkinson et al., 2008; Wallace et al., 2012), with choline given as supplements (500–2,600 mg/day of
choline) for 2–12 weeks or just once a week. Three others were cross-sectional studies within long-term
cohorts (Cho et al., 2006; Chiuve et al., 2007; Lee et al., 2010b), involving 6,069 subjects of which 1,325
were men. The results from RCTs with supplements are inconsistent. RCTs with choline doses of 500 and
1,000 mg/day showed no decrease in plasma tHcy concentration (Atkinson et al., 2008; Wallace et al.,
2012). However, a dose of 2,600 mg/day (as PC) over 2 weeks resulted in a signiﬁcant decrease in
fasting plasma tHcy concentration (mean  SD: 15.6  4.0 vs 13.6  2.5 lmol/L; p < 0.0001) and,
compared to placebo, a signiﬁcantly lower rise (p < 0.0001) in plasma tHcy concentration following a
methionine load (0.1 g/kg bw) (Olthof et al., 2005). The cross-sectional studies showed an inverse
relationship between dietary choline intake (that ranged in quintiles from around 230 to 400 mg/day)
and fasting plasma of tHcy concentrations.
The Panel notes that many factors besides dietary or endogenous choline determine the tHcy
concentration in plasma. The Panel concludes that neither fasting nor post-methionine load tHcy
concentrations in plasma can be used for setting DRVs for dietary choline.
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2.4.4. Urinary betaine excretion
The Panel notes that betaine in urine may be of dietary origin or produced in the body from choline
(Section 2.3.6.1.2). The rise in urinary DMG concentration, the second product of BHMT activity
(Figure 2 and Section 2.3.6.1.3), after a choline supplement or a high-choline meal, suggests that
choline-derived betaine is primarily used for Hcy remethylation in the liver (rather than fulﬁlling the
other functions of betaine in the body).
The Panel concludes that urinary betaine excretion is not predictably related to dietary choline
intake and, therefore, cannot be used for setting DRVs for dietary choline.
2.4.5. Conclusions on biomarkers
The Panel considers that the available data do not allow concluding on a dose–response
relationship between choline intake and plasma choline concentration or the use of this concentration
as a biomarker of choline status. The Panel also considers that plasma free choline concentrations are
not suitable to derive DRVs for dietary choline. Plasma concentrations of PC, betaine, DMG, tHcy or
TMAO, erythrocyte PC concentration, or urinary betaine and TTMA excretion can neither be used to set
DRVs for dietary choline.
2.5. Effects of genotypes involved in choline metabolism
Several SNPs in genes coding for enzymes in choline metabolism and in methyl-group metabolism
can alter the requirement for choline and determine the likelihood of developing signs of choline
deﬁciency (Section 2.2.2.1) with low dietary choline intakes. For example, MTHFD1 (Sections 2.2.2.1
and 2.3.7) is a trifunctional enzyme responsible for generating and interconverting 1-carbon-
substituted THF cofactors from formate. MTHFD1 mutations can impact both Hcy remethylation and
thymidylate (dTMP) biosynthesis.
Genetically modiﬁed mice with defective MTHFR activity become choline deﬁcient (Schwahn et al.,
2003b) and 15–30% of humans have genetic polymorphisms that alter the activity of this enzyme
resulting in a higher requirement for folate, and potentially indirectly for choline if folate intake is lower
than the requirement (Rozen, 1996; Wilcken et al., 1996).
da Costa et al. (2006a) (Sections 2.2.2.1. and 5.1.1.3 and Appendices C and D) performed a
controlled trial in 57 subjects (26 men and 31 women), aged 18–70 years, to determine whether
susceptibility to develop organ dysfunction due to choline deﬁciency was inﬂuenced by common
genetic polymorphisms. The choline depletion/repletion study design is described in Section 5.1.1.2.
Sixty-eight percent of the subjects (n = 39) developed organ dysfunction on the low-choline diet,
which was resolved during choline repletion. Mean plasma choline concentrations decreased by almost
30% (from 9.8 to 7.1 lmol/L), irrespective of development of organ dysfunction. Susceptibility to
choline deﬁciency was not affected by BHMT +742G?A SNP (rs3733890) in this study.
Niculescu et al. (2007) (Section 5.1.1 and Appendix D) performed a study in 33 subjects (14 men
and 19 women), aged 20–67 years, to examine the effects of a low-choline diet on gene expression in
subjects who developed organ dysfunction due to low choline intake, those who did not, and the
potential role of four SNPs in genes involved in folate and choline metabolism (PEMT rs12325817,
MTHFD1 rs2236225, CHDH rs9001 and rs12676). The choline depletion/repletion study design is
described in Section 5.1.1.2. Blood was collected after the baseline diet and after the low-choline diet,
and peripheral lymphocytes were used to measure gene expression and for SNP genotyping. The low-
choline diet resulted in underexpression of 152 genes and overexpression of 107 genes. Differences in
gene expression changes were noted between those who developed organ dysfunction and those who
did not. Analyses using group clustering and gene ontology showed that changes in gene expression
related to the experimental diets were signiﬁcantly altered by the SNPs examined.
Appendix C lists the enzymes (PEMT, MTHFD1, CHDH, BHMT, choline kinase isoform A or B (CHKA
or CHKB), CCT, SLC44A1, MTHFR), which have SNPs with known qualitative impact on choline
requirement and/or are associated with an increased risk of developing organ dysfunction or other
health outcomes, including birth defects, when consuming a low-choline diet. In particular, some
speciﬁc polymorphisms of the genes for PEMT, CHDH and MTHFD1 were shown to increase the
dependency on dietary choline intake (Appendix C).
According to the review by Au et al. (2010), it may not be accurate to include or exclude risk
contribution of the tested genes investigated in epidemiological studies on neural tube defects (NTDs),
some of them having limitations in study design, that potentially affect the power of statistical analysis,
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thus providing conﬂicting conclusions. For complex diseases like NTDs, it is anticipated that the risk of
a disease-associated allele is between 1 and 2, and over 2,000 samples (cases plus controls) would be
needed to provide statistical power of 80% to assess a risk of 1.8–2 of a disease locus with a SNP
allele frequency of 0.1. Double or quadruple the controls would be needed if unmatched controls are
used, to adjust for confounding factors.
The Panel notes that many SNPs have been described for genes coding for eight enzymes
(Appendix C) involved in choline or methyl-group metabolism, and that carrier frequency in mixed
populations can be up to about 70%. Kohlmeier et al. (2005) mention a personal communication by K.
Meyer and P.M. Ueland that the distribution of polymorphic variants of MTHFR and MTHFD1 in North
Carolina (Appendix C) largely agreed with that of North European populations (Norwegian Colorectal
Cancer Prevention (NORCCAP) study).
The effects of the PEMT polymorphism rs12325817, on the likelihood of development of signs of
organ dysfunction (mainly liver) when choline intake is experimentally restricted to ≤ 50 mg/70-kg bw
per day, have been investigated most often. The risk of organ dysfunction is higher in postmenopausal
than in premenopausal women and is increased by simultaneous restriction in folate intake. Due to the
experimental design of choline depletion/repletion studies with a low choline intake during the
depletion period (≤ 50 mg/70-kg bw per day) (Section 5.1.1), and because of the lack of data on the
relationship between habitual choline intakes and signs attributable to choline deﬁciency in
populations, the Panel notes that the amount of dietary choline needed to prevent such signs cannot
be predicted with conﬁdence.
2.5.1. Inﬂuence of polymorphisms in pregnancy and lactation
Polymorphisms in the MTHFD1 gene and the BHMT gene, coding for enzymes involved in choline
metabolism, were identiﬁed as potential candidates for association with choline concentrations in
maternal plasma and breast milk (Fischer et al., 2010b) (Sections 2.3.3, 2.3.6.3, 2.4.1.2, 5.1.3, 5.2.5).
In the RCT by Fischer et al. (2010b), the authors also investigated whether maternal
polymorphisms (370 SNPs in 10 genes involved in choline metabolism) modiﬁed the response of
maternal plasma and breast milk choline concentrations (measured at 45 days post partum) to choline
supplementation (compared with placebo). These SNPs were tested in linear regression models, with
choline metabolites as the response and homozygous wild-type, heterozygous wild-type and
homozygous variant alleles of SNPs, as well as choline intake (from food and supplements), as
predictors. In these models, ﬁve SNPs in the MTHFR gene were identiﬁed in the placebo group that,
for most of them, reduced the slope of the response curve of free choline concentration in breast milk
to choline intake (p < 0.05). In addition, outliers previously identiﬁed by the authors (in a ﬁrst analysis
of the relationship between intake and concentrations in breast milk or plasma) were tested for
combinations of shared SNPs. In this analysis, three subjects of the placebo group were identiﬁed with
ﬁve SNPs in common in the MTHFD1 gene and who had exceptionally high breast milk choline
concentrations (in relation to choline intake). Five participants were also identiﬁed with two SNPs in
common in the BHMT gene, and four of these subjects had lower than average plasma free choline
concentrations (in relation to choline intake).
Besides the choline intake of the mother (Section 2.3.6.3 and Appendix A), the Panel notes that
polymorphisms in genes coding for enzymes involved in choline and methyl-group metabolism,
particularly if they occur in combinations, can inﬂuence the amount of choline secreted into breast
milk. The Panel considers that the available data on polymorphisms in genes are insufﬁcient to predict
choline concentrations in breast milk.
2.5.2. Conclusion on effects of genotypes
The Panel concludes that SNPs can enhance or reduce the function of enzymes involved in choline
metabolism. This can inﬂuence the requirement for choline and, moreover, can determine the
susceptibility to dietary choline deﬁciency. The Panel considers that particularly some speciﬁc
polymorphisms of the genes for the enzymes PEMT, CHDH and MTHFD1 are known to increase the
dependency on dietary choline intake. Since their frequency in populations vary and their impact on
dietary choline requirement may be inﬂuenced by dietary habits, no conclusions can be drawn from
available studies on predictable variations in individual choline requirements.
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3. Dietary sources and intake data
3.1. Dietary sources
Total choline content is highest in eggs (raw egg yolk: about 670 mg/100 g food, whole raw fresh
egg: about 290 mg/100 g food) followed by meats and ﬁsh, whole grains, vegetables and fruit, and
fats and oils (median content of fats and oils: about 5 mg/100 g food) (USDA, 2015) (Section 3.2.1).
The proportion of different choline compounds in food can change by preparation. For example,
cooking decreases the concentration of free choline and increases the content of PC per 100 g food,
while mincing of raw vegetables decreases the content of PC by activating phospholipase D with the
release of free choline and phosphatidic acid (Zeisel et al., 2003). The implications of such changes in
choline compounds for human nutrition are unknown.
Human milk is rich in choline (Section 2.3.6). Ilcol et al. (2005) showed that the distribution of
choline compounds in human milk, and bovine-derived and soy-protein based formulae from different
manufacturers differed considerably, e.g. soy-derived formulas had much less SPM than human milk.
In the EU, the addition of choline to infant formula is mandatory with a minimum level of 7 mg and
a maximum level of 50 mg of choline/100 kcal and the total phospholipid concentration must be not
higher than 2 g/L.3
Currently, choline, choline chloride, choline bitartrate and choline citrate may be added to food
intended for infants and young children, food for special medical purposes, and total diet replacement
for weight control in the EU.9 CDP-choline (citicoline) has been evaluated as novel food by EFSA and
no safety concerns were raised (EFSA NDA Panel, 2013a).10 Choline and choline compounds can be
found in dietary supplements.
3.2. Dietary intake
3.2.1. Dietary intake in EU countries
The Panel notes that no food composition data with respect to choline are available at the
European level, and that there is a lack of reliable measurements of choline content in foods in the EU.
The Panel refers to the study by Vennemann et al. (2015), which used, with the aim at assessing
choline intake in the EU, the total choline composition data from the release 26 of the National
Nutrient Database for Standard Reference from the US Department of Agriculture (USDA database;
issued in November 2013) (USDA, 2013) (Section 3.1). Total choline content of US foodstuffs was
calculated by USDA as the sum of free choline, GPC, PChol, PC and SPM.
In the assessment by Vennemann et al. (2015), food consumption data from the EFSA
Comprehensive European Food Consumption Database (EFSA, 2011), classiﬁed according to FoodEx2
classiﬁcation, were used. This assessment includes food consumption data from 12 dietary surveys
from nine EU countries (Finland, France, Germany, Ireland, Italy, Latvia, the Netherlands, Sweden and
the United Kingdom). These surveys used 3–7-day food records, 24-h recalls performed on at least
2 days or 48-h recalls. Individual data from these nationally representative (except for the Finnish
surveys in children) surveys undertaken between 2000 and 2011 were available to EFSA. In this
assessment by Vennemann et al. (2015), the nutrient composition data was obtained for 2,684 food
items by recoding the USDA nutrient composition food list (based on the LanguaL food description
thesaurus) to FoodEx2 classiﬁcation (used for the food consumption data). Nutrient intake calculations
were performed only on subjects with at least two reporting days. Choline intake from dietary
supplements was not assessed. Mean, medians, 5th and 95th percentiles of intake of the population,
per survey, age, class and sex, were calculated.
Data were available from four surveys for children aged from 1 to < 3 years, from seven surveys
for older children, and from eight surveys for adults (including one survey during pregnancy). Total
choline intake mean estimates ranged from 151 to 210 mg/day in children aged from 1 to < 3 years,
177–304 mg/day in children aged from 3 to < 10 years, 244–373 mg/day in children aged from 10 to
9 Regulation (EU) No 609/2013 of the European Parliament and of the Council of 12 June 2013 on food intended for infants and
young children, food for special medical purposes, and total diet replacement for weight control and repealing Council
Directive 92/52/EEC, Commission Directives 96/8/EC, 1999/21/EC, 2006/125/EC and 2006/141/EC, Directive 2009/39/EC of
the European Parliament and of the Council and Commission Regulations (EC) No 41/2009 and (EC) No 953/2009, OJ L 181,
29.6.2013, p. 35.
10 Commission Implementing Decision 2014/423/EU of 1 July 2014 authorising the placing on the market of citicoline as a novel
food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council, OJ L 196, 3.7.2014, p. 24.
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< 18 years. Total choline intake mean estimates ranged from 269 to 468 mg/day in adults aged from
18 to ≥ 75 years, i.e. from 332 to 468 mg/day in men and from 269 to 404 mg/day in women of this
age range, respectively. From one survey in Latvia, the total choline intake mean estimate was
336 mg/day in pregnant adolescents and 356 mg/day in pregnant women.
Data on infants (< 1-year-old) were available from three out of the seven surveys, namely from
Finland, Germany and Italy11 (data not shown in the study by Vennemann et al. (2015)). The total
choline intake mean estimates in infants ranged from 75 to 127 mg/day. The Panel notes the
limitations in the methods used for assessing breast milk consumption in infants and related
uncertainties in the choline estimates for infants.
Choline intake estimates are also available from a convenience sample of Flemish women (aged
18–35 years) (Pauwels et al., 2015). In this study, food consumption was assessed by FFQs covering
51 food items that had been selected because they were part of the Belgian diet and/or were the main
contributors for one of four methyl-group donors (including choline), and the USDA database was also
used as food composition database for choline. Despite important methodological differences with the
intake assessment described above from the study by Vennemann et al. (2015), and the speciﬁc
population group investigated, choline intake estimates in Flemish women (mean  SD: 286.6 
105.1 mg/day) were in the same order of magnitude of the estimates produced by Vennemann et al.
(2015) for several EU countries.
3.2.2. Dietary intake in non-EU countries
In view of the limited data on choline intake published in the EU, the Panel again refers to the
study by Vennemann et al. (2015), which compared their estimates with four studies carried out in
non-EU countries in adult men and women in the USA, New Zealand and Taiwan (Chu et al., 2012;
USDA, 2012; Mygind et al., 2013), and pregnant and lactating women in Canada, followed from
the ﬁrst or second trimester to 3 months post partum (Lewis et al., 2014). Two of these studies
used nationally representative data (Chu et al., 2012; USDA, 2012), all studies used 24-h recalls or
three-day food records as dietary assessment methods (but not FFQs), were cross-sectional (apart
from the study on pregnant and lactating women) and used the same composition database (USDA
database) as Vennemann et al. (2015) although from different releases.
The mean choline intake estimates in adults was 415 and 279 mg/day in US men and women,
respectively (USDA, 2012), 316 mg/day in women aged 18–40 years in New Zealand (Mygind et al.,
2013) and 372 and 265 mg/day in men and women aged 18–64 years, respectively, in Taiwan (Chu
et al., 2012). The mean ( SD) choline intake in pregnant and lactating women in Canada ranged
between 340  148 in the second trimester and 346  151 mg/day at 3 months post partum (Lewis
et al., 2014).
3.2.3. Conclusion on dietary intake
The Panel notes that mean choline intake estimates in adults ranged from 269 to 468 mg/day in
national surveys from seven EU countries (Vennemann et al., 2015), was about 290 mg/day in one EU
country (Pauwels et al., 2015), and were between 265 and 415 mg/day in three studies conducted in
non-EU countries (Chu et al., 2012; USDA, 2012; Mygind et al., 2013). The Panel also notes that mean
choline intake was about 350 mg/day in the only EU survey on pregnant women considered in
Vennemann et al. (2015), as well as in one study on pregnant or lactating women in one non-EU
country (Lewis et al., 2014). The Panel concludes that the choline intake data resulting from the
assessment by Vennemann et al. (2015) in EU countries are generally of the same magnitude as the
intakes of the published studies available in adults in EU (Pauwels et al., 2015) and non-EU countries
(Chu et al., 2012; USDA, 2012; Mygind et al., 2013; Lewis et al., 2014).
4. Overview of dietary reference values and recommendations
To date, DRVs for choline have only been proposed by IOM (1998).
11 The proportions of breast-fed infants were 58% in the Finnish survey, 40% in the German survey, 44% in the Italian survey.
Most infants were partially breast-fed. For the Italian and German surveys, breast milk intake estimates were derived from the
number of breastfeeding events recorded per day multiplied by standard breast milk amounts consumed on an eating
occasion at different ages. As no information on the breastfeeding events was reported in the Finnish survey, breast milk
intake was not taken into consideration in the intake estimates of Finnish infants.
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4.1. Adults
IOM (1998) set Adequate Intakes (AIs), since data were not sufﬁcient for deriving an Estimated
Average Requirement (EAR) and a Recommended Dietary Allowance (RDA). The AIs for choline were
based on data on the prevention of liver damage, as assessed by measuring serum ALT
concentrations. The estimate was considered by the IOM as being uncertain because it was based on
a single RCT by Zeisel et al. (1991) (depletion/repletion study, Section 5.1 and Appendix D). This study
examined serum ALT activity in 16 healthy male hospitalised volunteers. They were supplemented with
500 mg choline/day for 1 week, then randomised to receive for three additional weeks either the
choline-supplemented diet (control group, n = 7) or the same diet without choline but with cellulose as
placebo (n = 8), then all subjects consumed the choline-supplemented diet during the ﬁfth week of
the study. A choline intake of 500 mg/day, which is approximately 7 mg/kg bw per day using the
mean body weight for the control group, i.e. 74.4 kg, prevented ALT abnormalities in these healthy
men. Thus, the AI was set at 550 mg/day after rounding, considering the US reference weight of
76 kg for men (National health and nutrition examination survey (NHANES) III, 1988–1994).
The IOM noted that, at that time, no studies undertaken in healthy women following a choline
deﬁcient diet were available. However, from an intervention study (Buchman et al., 1995) on one man
and three women with hepatic steatosis receiving total parenteral nutrition containing 1–4 g/day of
choline chloride for 6 weeks, the IOM concluded that women were just as likely as men to develop low
plasma choline concentrations and fatty liver. To set an AI for women, the IOM assumed that the data
used to set an AI for men could be used, even though women may use choline more efﬁciently, thus
the derived AI for women was set at 425 mg/day based on the US reference weight of 61 kg for
women (NHANES III, 1988–1994). The IOM noted some evidence that transport across the blood–
brain barrier is diminished in older adults (60–85 years, compared to younger adults aged
20–40 years), suggesting the possibility of a higher requirement than for younger adults (Cohen et al.,
1995). Nevertheless, for older adults, no adjustment was made to the AI.
4.2. Infants and children
For breast-fed infants from birth to 6 months, IOM (1998) set an AI of 125 mg/day. This AI was
based on an average breast milk consumption of 0.78 L/day (Hofvander et al., 1982; Butte et al.,
1984; Chandra, 1984; Neville et al., 1988; Allen et al., 1991) and an average choline concentration of
160 mg/L. This average choline concentration was obtained from 15 healthy US mothers exclusively
breastfeeding and followed from 30 days up to 85 days post partum (Zeisel et al., 1986) and 33
healthy US mothers participating in the study during postnatal days 27–32 (Holmes et al., 1996). For
older infants aged 7–12 months, the AI was extrapolated upwards from the AI for infants from birth to
6 months by allometric scaling and using US reference weights (NHANES III, 1988–1994), and was set
at 150 mg/day. This value was conﬁrmed by the downwards extrapolation from the AI for adults by
allometric scaling using a growth factor, which gave the same result.
In the absence of data on which to base an EAR or AI for choline for children, IOM (1998) extrapolated
the AIs for children aged 1–18 years from adult values, by allometric scaling using growth factors.
4.3. Pregnancy
IOM (1998) concluded that an increase in the AI to support pregnancy should be based on the fetal
and placental accumulation of choline. The IOM took into account animal data on choline
concentration in adult tissues (Pomfret et al., 1989), organ weight in the human fetus (Widdowson,
1963) and human data (n = 7) on choline concentration in placental tissue (Welsch, 1976), and
considered an average choline concentration of 321 mg/kg of fetal and placental tissue combined. The
IOM assumed that there is no extra choline synthesis by the mother during pregnancy, and that there
is no choline synthesis by the placenta or fetus. Thus, the required additional dietary intake of choline
for 10 kg of tissue, that comprises the fetus (3 kg) and organs of pregnancy (7 kg), was calculated to
be approximately 11 mg/day throughout pregnancy. The AI for choline was thus set at 450 mg/day
(after rounding) for pregnant adolescent and adult women.
4.4. Lactation
IOM (1998) proposed an additional intake of 125 mg/day for lactating women aged 14–50 years,
considering an average breast milk production of 0.78 L/day (Hofvander et al., 1982; Butte et al.,
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1984; Chandra, 1984; Neville et al., 1988; Allen et al., 1991) and an average choline concentration of
breast milk of about 160 mg/L.
An overview of DRVs for choline for infants, children, adults, pregnant or lactating women is
presented in Table 1.
5. Criteria (endpoints) on which to base Dietary Reference Values
5.1. Indicators of choline requirement
Plasma choline concentration may increase when intake is increased, and decreases by up to 50%
when dietary intake is severely restricted (Zeisel et al., 1991; Savendahl et al., 1997) (Section 2.4.1).
However, the plasma choline concentration of healthy subjects is determined not only by diet, but also
by endogenous choline synthesis, potential release of choline from tissue phospholipids, microbial
metabolism of dietary choline in the gut and degradation of choline via betaine (Section 2). The result
of these different inﬂuences on plasma choline concentration is unpredictable. As indicated in
Section 2.4.5, the Panel concludes that the available data do not allow concluding on a dose–response
relationship between choline intake or choline status and plasma choline concentration. The Panel also
concludes that plasma concentrations of choline, PC, betaine, DMG, tHcy or TMAO, erythrocyte PC
concentration, or urinary betaine and TTMA excretion cannot be used to set DRVs for dietary choline
(Section 2.4.5).
5.1.1. Adults
Zeisel and co-workers performed 11 choline depletion/repletion studies in different groups of both
women and men that all followed a similar design. For this reason, the characteristics of these studies
are summarised below, while detailed information is available in Appendix D.
5.1.1.1. Study goals
The goals differed between the studies. The ﬁrst study evaluated the changes in choline status and
liver function of healthy humans fed a choline-deﬁcient diet (Zeisel et al., 1991). Another study
assessed whether choline deﬁciency decreases the capacity to methylate homocysteine (da Costa
et al., 2005) (Section 2.2.2.1). One study investigated the inﬂuence of genetic variants of folate
metabolism on susceptibility to choline deﬁciency symptoms (Kohlmeier et al., 2005). Another assessed
whether SNPs in genes coding for enzymes involved in choline metabolism inﬂuence the dietary
requirement for choline and whether choline deﬁciency is associated with apoptosis and DNA damage
Table 1: Dietary Reference Values for choline for infants, children, adults, pregnant or lactating
women
IOM (1998)(a)
Age (months) 7–12
All (mg/day) 150
Age (years) 1–3
All (mg/day) 200
Age (years) 4–8
All (mg/day) 250
Age (years) 9–13
All (mg/day) 375
Age (years) 14–18
Boys (mg/day) 550
Girls (mg/day) 400
Age (years) ≥ 19
Men (mg/day) 550
Women (mg/day) 425
Pregnancy (mg/day) 450
Lactation (mg/day) 550
(a): Adequate Intakes. IOM: U.S. Institute of Medicine of the National Academy of Sciences.
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(da Costa et al., 2006b). One study investigated the inﬂuence of sex and menopausal status on dietary
requirement of choline (Fischer et al., 2007). Another investigated the inﬂuence of genetic
polymorphisms in PEMT, MTHFD1, CHDH on susceptibility for organ dysfunction in choline deﬁciency
(Niculescu et al., 2007). One study estimated whether the risk for choline deﬁciency induced organ
dysfunction in premenopausal women is dependent on the number of variant PEMT rs12325817 alleles
in premenopausal women and whether oestrogen can decrease the risk in postmenopausal women
(Fischer et al., 2010a). One study assessed whether metabolomic proﬁling of plasma can predict organ
dysfunction in choline deﬁciency (Sha et al., 2010). One study investigated how diet and choline
deﬁciency inﬂuence the human gastrointestinal tract microbiome and the development of liver steatosis
(Spencer et al., 2011). One study assessed whether plasma PC-DHA concentration is a non-invasive
marker for liver PEMT activity (da Costa et al., 2011). Finally, one study identiﬁed effect alleles in a
number of SNPs of genes known to be of inﬂuence on the dietary requirement of choline (da Costa
et al., 2014). Characteristics and outcomes of these 11 studies are compiled in Appendix D.
5.1.1.2. Study design
The design was similar in all studies (Appendix D), and was the following: a 7–10 day baseline diet,
followed by a 42-day choline depletion diet, and then a choline-repletion diet (3–40 days). During the
10-day baseline diet, the subjects received normal foods providing 550 mg choline and 50 mg betaine/
70-kg bw per day. During the choline-depletion diet, the subjects received foods providing < 50 mg
choline and 6 mg betaine/70-kg bw per day for up to 42 days (with or without a folic acid supplement
(100 or 400 lg/day according to study objective)), or until they were deemed choline-deﬁcient and/or
developed signs of organ dysfunction. In some studies, the participants were randomised into a
depletion group and a control group that continued on the baseline diet. More details on the design
per study are provided in Appendix D.
Muscle and liver dysfunction associated with choline deﬁciency was deﬁned by the authors as a
ﬁvefold or greater increase in serum CK activity, a 1.5-fold or greater increase in AST, ALT,
c-glutamyltransferase (GGT) or lactate dehydrogenase (LDH), and/or a 28% or greater increase in liver
fat content measured by computerised tomography (CT) or magnetic resonance imaging (MRI)
compared with baseline and, depending on the study, estimated on day 21 and 42 of depletion. The
same parameters were measured to assess reversion of the damage.
Those who completed the 42-day depletion phase without the development of hepatic steatosis
were put on a diet providing 550 mg choline/70-kg bw per day for 3 days and then discharged.
Choline-deﬁcient subjects were put on a diet with stepwise increases in choline intake, in sequential
10-day periods of 137.5, 275, 412.5 or 550 mg choline/70-kg bw per day. Those who showed signs of
organ damage with increases of CK activity > 10,000 U/L were immediately switched to the choline-
repletion diet or directly to 850 mg choline/70-kg bw per day or to an ad libitum diet. Status was
monitored regularly using blood and urine samples (at screening, day 1, at the end of each dietary
phase, and every 3–4 days during the intervention).
5.1.1.3. Number of subjects and choline intake
The number of subjects ranged from 8 to 72 per study, and some of the subjects participated in
several studies (Appendix D). The total number of subjects (in all studies) investigated is not quite
clear, because subjects recruited in 2001 and 2007 (approximately 150–160) were investigated in
different studies. The susceptibility for organ dysfunction by choline depletion was signiﬁcantly
inﬂuenced by polymorphisms of the MTHFD1 (e.g. rs2236225), CHDH, CHK, CLCA441 and PEMT (e.g.
rs12325817) genes (Section 2.5), by being male or postmenopausal and not receiving oestrogen
therapy. Folic acid supplementation (400 lg/day) did not prevent the development of organ
dysfunction during choline depletion (Kohlmeier et al., 2005).
In the depletion/repletion study that investigated the inﬂuence of sex and menopausal status on
choline requirement (Fischer et al., 2007) in 57 healthy adult subjects (26 males, 16 premenopausal
and 15 postmenopausal women), aged 18–70 years, 20 out of 26 (77%) men developed choline
deﬁciency signs, six already in the baseline phase with 550 mg choline/70-kg bw per day. In this study,
12 out of 15 (80%) postmenopausal women and 7 out of 16 (44%) premenopausal women developed
choline deﬁciency signs on the low-choline diet. In total, 39 out of 57 (68%) male or female subjects
developed signs of choline deﬁciency. In the same study, the authors also looked for differences in
clinical chemistry data between subjects who developed choline deﬁciency and subjects who did not
(apart from the parameters used to deﬁne choline deﬁciency-related organ dysfunction). Between
sexes and life-stage groups, there were no signiﬁcant differences in plasma concentrations of free
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choline, betaine, DMG, tHcy, which all decreased upon depletion, and of SAM and SAH, which did not
change. Plasma PC concentrations, however, decreased only in subjects who developed organ
dysfunction.
The amount of choline needed to replete subjects with signs of organ dysfunction differed between
subjects (Fischer et al., 2007) as shown in Table 2. In all the other studies mentioned in Appendix D,
this was not reported. Disregarding missing data as well as sex differences because the numbers are
too small, 10 out of 39 choline-deﬁcient subjects were repleted with 137.5 mg/70-kg bw per day, three
with 275, ﬁve with 412.5, and 13 needed 550 or more than 550 mg/70-kg bw per day (or an
ad libitum diet) including the six men with signs of choline deﬁciency already on the baseline diet with
550 mg choline/70-kg of bw, while the data from eight subjects were completely missing.
Out of 25 subjects12 who showed signs of choline deﬁciency after experimental choline depletion
and for whom the amount of choline needed to replete them was available, the Panel notes that 18,
i.e. about 70%, needed up to about 400 mg choline/70-kg bw per day for repletion. The Panel also
notes that this percentage decreased to 58% when the six men with signs of choline deﬁciency
already during the baseline period with 550 mg choline/day (and therefore presumably with a higher
choline requirement) were taken into account (Fischer et al., 2007). The Panel did not consider the 18
individuals who did not show signs of choline deﬁciency with 50 mg/70-kg bw per day. It is not known
if they would have developed signs of choline deﬁciency with a longer period of choline depletion
(> 6 weeks). The Panel notes that data are missing for the precise amount of choline needed for
repletion in eight subjects.
The Panel notes that the subjects of this trial (Fischer et al., 2007) were classiﬁed according to
polymorphisms in genes coding for PEMT, CHDH, BHMT (da Costa et al., 2006a) and for MTFHR,
MTFHD1 and the reduced folate carrier 1 (RFC1) (Kohlmeier et al., 2005) (Appendices C and D). The
susceptibility to develop organ dysfunction on the low-choline diet was signiﬁcantly increased
(p = 0.002, odds ratio (OR): 25; 95% CI: 2–256) (18 out of 23 carriers of the C allele) in women
carriers of the PEMT promoter SNP rs12325817 (744 G?C), and speciﬁcally in postmenopausal
women (p = 0.03, OR: 42; 95% CI: 1–1,348). In contrast, being a carrier of the CHDH gene SNP
rs9001, +318 A?C) had a protective effect on the susceptibility to develop organ dysfunction
(p = 0.03, OR: 0.2; 95% CI: 0.05–0.7), while the CHDH SNP rs12676 (+432 G?T) did not, except in
premenopausal women. The SNPs PEMT rs7946 (+5465 G?A) and BHMT rs3733890 (+742 G?A)
were not associated with susceptibility to organ dysfunction on a low-choline diet. Only the MTHFD1
SNP (1958G?A) rs2236225 carriership increased the susceptibility to develop signs of choline
deﬁciency when the choline intake was low, and that only in premenopausal women (OR: 85, 95% CI:
3–2,418), and this susceptibility was attenuated by folate supplementation.
There are indications that choline deﬁciency during depletion/repletion studies (da Costa et al.,
2006a; Niculescu et al., 2007) (Appendix D) may increase cell apoptosis and induce DNA damage
Table 2: Amount of choline needed to replete subjects after experimental choline depletion (Fischer et al.,
2007)
Study subjects n
No signs of
choline
deﬁciency with
low-choline
diet
Signs of choline
deﬁciency, with
choline intake (mg/
70 bw per day) of
Choline needed for repletion, total
mg/70-kg bw per day
Missing data
for repletion
n 550 mg, n 50 mg, n 137.5, n 275, n 412.5, n ≥ 550, n n
Men 26 6 6* 14 6 2 3 7* 2
Premenopausal
women
16 9 – 7 1 – – 2 4
Postmenopausal
women
15 3 – 12 3 1 2 4 2
Total 57 18 6* 33 10 3 5 13 8
n: number of subjects; bw: body weight.
*Six men showed already signs of choline deﬁciency with 550 mg choline/70-kg bw per day and consequently needed more than that
amount for repletion.
12 i.e. 10 + 3 + 5 + 136, indicated in Table 2.
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(assessed ex vivo/in vitro), for which the carriers of certain polymorphisms of PEMT and MTHFD1 were
more susceptible (Section 2.5). The Panel considers that the signiﬁcance of these studies is unclear.
There are also indications (Appendix D) that metabolomic proﬁling of the plasma of subjects on
baseline diet can predict susceptibility to develop organ dysfunction when deprived of dietary choline
(Sha et al., 2010) and that host factors and the gut microbiota (Spencer et al., 2011) both respond to
dietary choline intake and choline deﬁciency (Section 2.2.2.1).
5.1.1.4. Summary
Eleven available depletion/repletion studies in adults have demonstrated that dietary choline can
become insufﬁcient, e.g. within 6 weeks of a depletion phase with ≤ 50 mg choline/70-kg bw per day
(Appendix D). Only one of these studies reported the amount of choline needed to replete subjects
with signs of organ dysfunction (Fischer et al., 2007).
The Panel notes that experimental dietary depletion of choline led, in most (70–80%) of the male
and postmenopausal female subjects, to signs of organ dysfunction involving liver and muscle, but
only in 44% of premenopausal women (Fischer et al., 2007). These signs can be mild with biochemical
alterations only or can be severe with liver steatosis and muscle function impairment developing
rapidly. The susceptibility to develop organ dysfunction differs between subjects and is inﬂuenced by
genetics, sex, possibly the intestinal microbiome, and hormonal status (Section 2).
In addition, it is not known if the 18 subjects who have not developed signs of organ dysfunction
within 6 weeks would have done so in the long term, when their endogenous choline (PC) synthesis
would become insufﬁcient (Fischer et al., 2007). It is not known, but can be assumed, that the factors
that have an impact on the development of organ dysfunction also determine the amount of choline
needed to replete the body and reverse the signs of organ dysfunction and the requirement for dietary
choline.
According to the study by Fischer et al. (2007) described above, this requirement for dietary choline
in adults lies between about 130 and 500 mg choline/day, with most subjects needing more than
130 mg/day and some needing 500 mg/day or more (Table 2). From the 39 subjects who became
deﬁcient either with 550 or with 50 mg choline/70-kg bw per day, the data from 1413 are missing.
From the remaining 25, ten needed 137.5, three 275, ﬁve 412.5 and seven 550 mg choline/70-kg bw
per day or more. An intake of 412.5 mg choline/70-kg bw per day (i.e. 5.9 mg/kg bw per day) was
sufﬁcient to replete 18 of 25 deﬁcient subjects, that is about 70% or two-thirds.
The Panel considers that reliable markers of intake and status are not available (Section 2.4) and
that the study by Fischer et al. (2007) is too small and insufﬁcient to draw ﬁrm conclusions on the
Average Requirement (AR) for dietary choline in adults. However, as supportive evidence, it may
contribute to inform an AI that covers most of the population.
5.1.2. Infants and children
The Panel is unaware of any data in infants aged 7–11 months and children on indicators of choline
requirement.
5.1.3. Pregnancy and lactation
The Panel considered whether the calculation of choline transfer from the mother to the fetus and
of choline accretion in the fetus and placenta during pregnancy could be used to calculate the
additional need for dietary choline during pregnancy. However, a review of the available evidence
(Sections 2.3.3 and 2.3.4) showed that this was not feasible due to a lack of data.
The Panel then considered the available intervention studies on choline supplementation in
pregnant women in the second half of pregnancy, and in lactating women. Although none of the
biomarkers in plasma, urine or erythrocyte previously reviewed by the Panel are suitable biomarkers to
set DRVs for choline (Section 2.4.5), the Panel considers that they may be useful to assess potential
changes in choline metabolism in intervention studies in pregnant or lactating women.
5.1.3.1. Effect of total intake of choline in pregnant (vs non-pregnant) women and the
offspring
As described already in Sections 2.3.6.1 and 2.4.1.2, Yan et al. (2012) reported on plasma and
urine choline concentrations in 26 healthy pregnant women (third trimester) and 21 non-pregnant
13 8 + 6 (Table 2).
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controls who were randomly assigned to consume either 480 or 930 mg of choline/day from food and
supplements for 12 weeks (or until delivery). The diet provided an average of 380 mg/day of choline
(sum of all compounds), and supplemental choline was 100 or 550 mg/day (from choline chloride).14
Pregnant women had higher free choline concentration in plasma and urinary excretion of choline and
betaine than non-pregnant women throughout the study (Sections 2.3.6.1 and 2.4.1.2). Also, pregnant
women consuming 930 mg of choline/day had higher plasma concentrations of free choline than
pregnant women consuming 480 mg of choline/day. The lower circulating concentrations of choline-
derived methyl-group donors (betaine, DMG and sarcosine) observed in pregnant women compared
with non-pregnant women were suggestive of a greater use of these molecules in both maternal and
fetal compartments (Section 2.4.1.2).
This study also provided additional results. Plasma concentrations of the three methyl-group donors
(betaine, DMG and sarcosine) over the duration of the study were higher in pregnant women
consuming 930 mg choline/day compared with pregnant women consuming 480 mg of choline/day
(p < 0.016, p < 0.012, and p < 0.07, respectively), but without achieving the concentrations measured
in non-pregnant women consuming 480 mg choline per day. Urinary excretion of choline, betaine or
DMG in pregnant women was not different between the choline intake groups. However, urinary
excretion of sarcosine, methionine and Hcy were higher (46% higher, p = 0.029; 37% higher,
p = 0.02; 45% higher, p = 0.06, respectively) in the pregnant women consuming 930 mg/day,
compared with 480 mg/day. The results described above in plasma and in urine suggest that the
higher choline intake (930 mg/day) was predominantly used by the pregnant women, and not
excreted. However, in pregnant women, mean concentration of free choline in the placenta
(915  231 vs 941  309 nmol/g tissue) or in cord plasma (37.3  13 vs 32.5  7.5 lmol/L), and
anthropometric parameters or Apgar scores of the newborns did not differ between the lower and the
higher choline intake groups.
5.1.3.2. Effect of total intake of choline in pregnant (vs non-pregnant) women on the
dynamics of choline-related metabolic pathways
As indicated previously, the PC formed in the PEMT pathway contains substantial amounts of
LC-PUFAs, like DHA and ARA, while the PC formed in the CDP-choline pathway does not (Section 2.3.5).
Yan et al. (2013) investigated the effect of pregnancy on the dynamics of choline-related metabolic
pathways (Figure 2, Section 2.3.5) in the same study cohort of pregnant (third trimester) and non-
pregnant women investigated by Yan et al. (2012) who had received, after 6 weeks, 100 mg (of the
480 mg/day choline) and 200 mg (of the 930 mg/day choline) as deuterated choline (methyl-D9-
choline). In pregnant women (compared with non-pregnant women), the total plasma PC pool was
about 50% greater (Yan et al., 2013).
With regard to the CDP-pathway, the analysis of the different isotopomers of deuterated choline,
betaine and PC in plasma showed that in pregnant women (compared with non-pregnant women),
dietary choline was used more for PC production via the CDP-choline pathway than oxidised to
betaine. The higher choline intake (930 mg choline/day) in pregnant women restored the distribution
of dietary choline between PC synthesis via the CDP-choline pathway vs oxidation to betaine, to the
levels observed in non-pregnant women consuming 480 mg choline/day. With regard to PEMT
pathway, the analysis of the different isotopomers also showed that, in pregnant women (compared
with non-pregnant women), PC produced via PEMT is more catabolised to free choline (and this may
contribute to explain the rise in plasma choline in pregnancy), which is preferentially transferred to the
fetus. The higher choline intake (930 mg choline/day) enhanced the PEMT-mediated PC synthesis
relative to the CDP-choline pathway, compared to pregnant women consuming 480 mg choline/day.
West et al. (2013) investigated the effect of different choline intakes on choline-related lipid
metabolism in a separate analysis of the same study cohort of pregnant (third trimester) and non-
pregnant women investigated by Yan et al. (2012). At baseline, pregnant women had a greater
proportion of PC-DHA (% of total fatty acids) in both plasma (p = 0.01) and erythrocytes (p = 0.001)
than non-pregnant women. The higher choline intake (930 mg/day) did not affect the proportion of
PC-DHA in erythrocytes in pregnant women compared with an intake of 480 mg/day (whereas this was
the case in non-pregnant women, as described in Section 2.3.5.1). However, the higher choline intake
(930 mg/day) lowered the proportion of PC-ARA in erythrocytes in pregnant women (p = 0.02),
14 In addition to the strictly controlled diet, all subjects received 600 µg folic acid, 2.6 µg cobalamin, 1.9 mg vitamin B6 and
200 mg DHA per day.
Dietary Reference Values for choline
www.efsa.europa.eu/efsajournal 30 EFSA Journal 2016;14(8):4484
compared with an intake of 480 mg/day. The PC:PE ratio (Section 2.3.5.1) in plasma and erythrocytes
was not inﬂuenced by choline intake in pregnant or non-pregnant women.
5.1.3.3. Ex vivo studies in placental samples
From 24 subjects from the study by Yan et al. (2012) (12 each from the two choline groups),
placental tissue, cord blood leukocytes and maternal fasting venous blood at delivery were investigated
ex vivo by Jiang et al. (2012, 2013). In the group that consumed 930 mg/day choline compared with
the group that consumed 480 mg/day choline, the authors found that: (i) placental global DNA
methylation, histone methylation and the expression of a histone methyltransferase were higher; (ii)
placental methylation of the promoters of two cortisol-regulating genes, corticotropin releasing
hormone (CRH) and glucocorticoid receptor (NR3C1) was higher; (iii) placental CRH transcript
abundance was lower (about 40%, read on ﬁgure, concentration of the protein was not reported); (iv)
methylation of the CRH and NR3C1 promoter in cord blood leukocytes was lower; (v) the maternal
blood concentration of the protein antiangiogenic factor fms-like tyrosine kinase (sFLT1) at delivery
was lower (by about 30%, estimated from the ﬁgure); (vi) placental sFLT1 mRNA abundance was
lower (by about 30%, estimated from the ﬁgure, concentration of the protein was not reported).
5.1.3.4. Effect of total intake of choline on maternal plasma and breast milk during
lactation
The RCT by Fischer et al. (2010b) (Sections 2.3.3, 2.3.6.3, 2.4.1.2, and 5.1.1.1) demonstrated that
total intake of choline (from foods and supplements) is positively associated with the concentration of
free choline and choline-compounds in plasma of these lactating women (Section 2.4.1.2) and in breast
milk (Section 2.3.6.3). This study also showed that supplemental choline (750 mg/day choline, in
addition to a mean dietary choline intake of about 350 mg/day) compared with placebo increased the
mean concentration of free choline in plasma (Section 2.4.1.2) and in breast milk (Section 2.3.6.3).
In the previously described controlled feeding study by Davenport et al. (2015) (Sections 2.3.3,
2.3.6 and 2.4.1.2), lactating and control non-lactating women (the latter from the study by Yan et al.
(2012)) were randomised to consume 480 mg choline/day or 930 mg choline/day from food and
supplements7 for 10–12 weeks, and they all received, during the last 4–6 weeks, 20% of the total
intake of choline as deuterium labelled choline. Lactating (vs control) women showed a statistically
lower expression of three of the ﬁve genes investigated that code for enzymes/receptor involved in
choline metabolism, in leukocytes at baseline (mRNA abundance, p ≤ 0.05). They also showed a
higher plasma free choline concentration (Section 2.4.1.2) and lower urinary excretion of choline
metabolites (Section 2.3.6.1.2) throughout the study period. Lactating (vs control) women tended to
have a decreased oxidation of choline to betaine (Figure 2, Section 2.3.5), which would allow an
increase in the supply of intact choline to the mammary epithelium. The higher choline intake during
lactation (930 mg/day compared to 480 mg/day) signiﬁcantly increased the concentration of total
choline in breast milk and increased the supply of PEMT-derived choline metabolites in breast milk
(Section 2.3.6.3), as well as in blood.
5.1.3.5. Conclusion on pregnancy and lactation
In pregnant women (compared to non-pregnant women) (Yan et al., 2012, 2013; West et al.,
2013), the available studies:
• show increased urinary losses of choline and betaine;
• suggest a greater use of choline-derived methyl-group donors (DMG, betaine and sarcosine) in
both maternal and fetal compartments;
• suggest an enhanced PEMT activity to facilitate the transfer of LC-PUFA to the fetus via PC in
lipoproteins.
These studies on choline supplementation also suggest that a choline intake of 930 mg/day (from
food and supplements) in pregnant women (from the 27th week of gestation):
• increases (compared to 480 mg/day) maternal plasma choline concentration;
• increases maternal plasma concentrations of the three methyl-group donors (DMG, betaine
and sarcosine) compared with pregnant women consuming 480 mg/day, but without achieving
the concentrations measured in non-pregnant women consuming 480 mg/day;
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• restored the distribution of dietary choline between PC synthesis via the CDP-choline pathway
vs oxidation to betaine to the levels observed in non-pregnant women consuming 480 mg
choline/day;
• enhanced (compared to 480 mg/day) the PEMT-mediated PC synthesis vs the CDP-choline
pathway-mediated PC synthesis;
• had no impact (compared to 480 mg/day) on maternal urinary excretion of choline and
betaine, placental choline concentration, and cord plasma choline concentration.
These results may indicate a higher choline requirement in pregnancy than in non-pregnant
women, which would have to be supplied by additional dietary choline.
In lactating women, the available studies on choline supplementation on women either
supplemented from the 18th gestational week to 45 days post partum (Fischer et al., 2010b) or
recruited at 5 weeks post partum (Davenport et al., 2015), suggest that increased maternal choline
intake enhances the concentration of total choline in breast milk and increased the supply of PEMT-
derived choline metabolites in breast milk. As PEMT generates PC molecules enriched in DHA, the
supply of DHA from the lactating women to the infant might be facilitated. However, the fatty acid
composition of breast milk was not measured in these studies.
The Panel notes that no maternal clinical signs of choline deﬁciency (as described in
Sections 2.2.2.1 and 5.1.1.4) or no adverse outcomes in the offspring were reported in these studies
with a total intake of choline from foods and supplements of 480 mg choline/day in pregnant women,
or of about 350–480 mg choline/day in lactating women.
The Panel notes that these studies used high choline intakes (930 vs 480 mg/day from foods and
supplements in pregnant and lactating women in one study; about 1,100 mg/day from food and
supplements vs about 350 mg/day from foods in lactating women in another study). The Panel also
notes that the interpretation of the biochemical outcomes investigated is difﬁcult with the aim of
deﬁning choline insufﬁciency/adequacy in pregnancy.
The Panel notes that the ex vivo studies suggest that different maternal choline intakes during
pregnancy may induce epigenetic modiﬁcations of genes, and changes in genes involved in hormonal
and vascular physiology. However, such changes are difﬁcult to interpret and further research is
required.
The Panel concludes that calculation of the additional need for dietary choline during pregnancy
based on a calculation of choline transfer from the mother to the fetus and choline accretion in the
fetus and placenta during the duration of pregnancy is not feasible due to a lack of data
(Sections 2.3.3 and 2.3.4). The Panel concludes that, taken together, the studies on choline
supplementation provide evidence that pregnant or lactating women may need more choline than non-
pregnant non-lactating women. However, the data are not sufﬁcient to allow an estimate of the
additional requirement for dietary choline in pregnant or lactating women (above that of non-pregnant
non-lactating women). The Panel considers, however, that the additional intake of choline required to
compensate for the amount of total choline secreted in breast milk during the ﬁrst 6 months of
exclusive breastfeeding (Section 2.3.6.3) can be calculated.
5.2. Choline intake and health consequences
Since the report by SCF (1993), more data have become available on the relationship between
choline intake and NAFLD, CVD, different types of cancer, NTD and cognition. A comprehensive search
of the published literature, without time limit, was performed in August 2012 as preparatory work to
this Opinion in order to identify relevant health outcomes possibly associated with choline intake
through diet or supplementation, and which may inform the setting of DRVs for choline (El-Sohemy
et al., 2012). The main results of the preparatory work, together with new evidence from studies
subsequently published (in Pubmed) until November 2015 are summarised below.
Of the available RCTs investigating the health effects of choline, the results only of one RCT was
considered in this section, which reported dietary choline intake in addition to choline supplements.
The relationship between choline intake and chronic disease outcomes has been investigated mainly in
observational (prospective cohort, case–control) studies, where a positive, an inverse, or a lack of an
association between choline intake and disease outcomes might be confounded by uncertainties
inherent to the methodology used for the assessment of choline intakes, and by the effect of other
dietary, lifestyle or undeﬁned factors on the disease outcomes investigated. Taking into account the
uncertainty about the relationship between choline intake and biomarkers (Section 2.4), the Panel only
considered observational studies that include an assessment of choline intake, whereas studies on the
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relationship of plasma choline concentrations (or those of choline compounds) and health outcomes
with no quantitative data on choline intake (Wang et al., 2011) are not described below. In
observational studies, habitual dietary choline intake was generally estimated using a FFQ (ﬁlled-in
either once at baseline or at several time points, in prospective cohort studies) and composition data
from the USDA database (Section 3) and/or from the literature (Zeisel et al., 2003). For some
observational studies, choline intake from supplements was also assessed.
5.2.1. Non-alcoholic fatty liver disease
Dietary deﬁciency of choline can cause fatty liver (hepatic steatosis), which can result in NAFLD
(Section 2.2.2.1), which can be of different aetiologies and is the most common chronic liver disease
in developed countries. It is often associated with insulin resistance and dyslipidaemia, is a risk factor
for CVD and may progress to irreversible liver damage and liver cancer (Corbin et al., 2013; Lazo
et al., 2013; Byrne and Targher, 2014).
In two population-based prospective cohorts, Yu et al. (2014) investigated the association between
habitual dietary choline intake and risk of NAFLD in 56,195 women (recruited in 1997–2000
and followed-up through 2004–2007) and men (recruited in 2002–2006 and followed-up through
2008–2011), aged 40–75 years and free of hepatitis at baseline. NAFLD was diagnosed by sonography
(self-report). Mean daily choline intake was 412 mg (women) and 452 mg (men) in the highest
quintile, and 179 mg (women) and 199 mg (men) in the lowest quintile. After adjustment for potential
confounders,15 women and men in the highest quintile had a signiﬁcantly lower risk of NAFLD than
those in the lowest quintile, but not after further adjustments. In stratiﬁed analysis, the highest
quintile of choline intake remained inversely associated with risk of NAFLD compared with the lowest
quintile (OR: 0.72; 95% CI: 0.57–0.91, p trend = 0.007) only in women with a body mass index (BMI)
< 25 kg/m2 (but not in women with a BMI ≥ 25 kg/m2).
The Panel notes that, in one prospective cohort study, a lower choline intake was associated with a
higher risk of developing NAFLD in normal-weight women in adjusted stratiﬁed analysis. The
Panel concludes that the data on choline intake and risk of NAFLD are limited and cannot be used to
derive DRVs for choline.
5.2.2. Cardiovascular disease
A prospective cohort study, with an average follow-up of 8.1 years, investigated the association
between habitual dietary intake of choline and risk of CVD in 16,165 postmenopausal women aged
49–70 years and without prior CVD at baseline (Dalmeijer et al., 2008). After adjustment for potential
confounders, comparing the highest quartile of choline intake (> 329 mg/day) with the lowest
(< 266 mg/day) did not show a signiﬁcant relationship between choline intake and risk of total CVD,
coronary heart disease (CHD) or cerebrovascular accidents.
A prospective cohort study, with an average follow-up of 14 years, investigated the association
between habitual dietary intake of choline and risk of CHD, in 14,430 men and women without prior
CHD at baseline (mean age at baseline: about 54 years) (Bidulescu et al., 2007). After adjustment for
potential confounders, comparing the highest quartile of choline intake (> 363 mg/day) with the
lowest (< 217 mg/day) did not show a signiﬁcant relationship between choline intake and risk of CHD.
The Panel notes that two large prospective cohort studies on populations free of CVD at baseline
did not show a signiﬁcant association between choline intake and risk of CVD. The Panel concludes
that the data on choline intake and risk of CVD cannot be used to derive DRVs for choline.
5.2.3. Cancer
Choline is a methyl-group donor involved in the folate-dependent one-carbon metabolism
(Sections 2.2.1 and 2.3.5). Disturbances in this function that affect methylation or synthesis of DNA
may contribute to carcinogenesis (Section 2.2.2.1).
5.2.3.1. Colon/rectum
In a US prospective cohort study, Cho et al. (2007a) examined the relationship between total intake
of choline (via food and supplements) and risk of colorectal adenoma in 39,246 women free of cancer
15 Including age, total energy intake, education, income, physical activity, smoking, alcohol consumption, intake of protein,
saturated fat, polyunsaturated fat. Further adjustments for menopause, hypertension, diabetes mellitus, gallstones,
dyslipidaemia, BMI.
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or polyps at baseline and who underwent at least one endoscopy in the 18 years of follow-up. After
adjustment for potential confounders, a choline intake in the highest quintile (median: 383 mg/day)
was associated with a higher risk of colorectal adenomas compared with the lowest quintile (median:
261 mg/day) (relative risk (RR):1.45; 95% CI: 1.27–1.67; p trend < 0.001).
In a US prospective cohort study, Lee et al. (2010a) investigated the relationship between total
intake of choline (via food and supplements) and risk of colorectal cancers (CRCs) in 47,302 men
(40–75 years at baseline) free of cancer at baseline and with 18 years of follow-up. After adjustment
for potential confounders, a choline intake in the highest quintile, from either food or supplements,
was not associated with a higher risk of CRC compared with the lowest quintile.
In a case–control study, Lu et al. (2015) investigated the relationship between habitual dietary intake
of choline and risk of CRC, in 890 cases (aged 30–75 years) diagnosed up to 3 months previously,
compared with 890 age- and sex-matched controls. Choline intake (median, 25th and 75th percentiles)
was higher in controls (158, 120 and 202 mg/day) than in cases (133, 100 and 176 mg/day) (p < 0.01).
After adjustment for potential confounders, a choline intake in the highest quartile was inversely
associated with risk of CRC compared with the lowest quartile (OR: 0.54; 95% CI: 0.37–0.80;
p trend < 0.01). The Panel notes that the diet in this population provided about half of the dietary
choline and folate intake, and less red meat, poultry, eggs and milk than in the USA (Cho et al., 2007a).
The Panel notes the inconsistent results from observational studies on the association between
choline intake and risk of colorectal cancer.
5.2.3.2. Breast cancer
In a prospective cohort study with a follow-up of 12 years, Cho et al. (2007b) examined the
relationship between total intake of choline (via food and supplements) and risk of breast cancer in
90,663 premenopausal women, aged 26–46 years, and free of cancer at baseline. Median intake per
quintile ranged between 263 and 397 mg/day. After adjustment for potential confounders, choline
intake was not associated with breast cancer risk.
In a prospective cohort study, Cho et al. (2010) investigated the relationship between habitual
dietary intake of choline and risk of breast cancer in 74,584 women, who were either postmenopausal
in 1984 or became postmenopausal during 20 years of follow-up (mean age of about 62 years at
10-year follow-up). Median intake per quintile ranged between 260 and 396 mg/day. After adjustment
for potential confounders, choline intake was not associated with breast cancer risk.
In a population-based case–control study, Xu et al. (2009) investigated the relationship between
total intake of choline (via foods and supplements) and risk of (and mortality from) breast cancer and
all-cause mortality in 1,508 cases of breast cancer (diagnosed in 1996–1997 and followed through
2005) and 1,556 controls. After adjustment for age, choline intake (sum of all forms, ranging from
< 123 mg/day to > 247 mg/day) was not associated with risk of breast cancer. In addition, choline
intake (sum of all forms, ranging from < 142 to > 205 mg/day) was not associated with all-cause or
breast cancer mortality (while an inverse signiﬁcant relationship for both types of mortality was
observed comparing intake of free choline above about > 57 mg/day with that < 40 mg/day).
The Panel notes that three observational studies did not show a signiﬁcant association between
choline intake and risk of breast cancer. The Panel concludes that the data on choline intake and risk
of breast cancer cannot be used to derive DRVs for choline.
5.2.3.3. Other cancers (oesophageal, prostate and ovarian cancers)
In two population-based case–control studies, Ibiebele et al. (2011) evaluated the association
between habitual dietary intake of choline and risk of Barrett’s oesophagus (BE) and oesophageal
cancers. The ﬁrst study compared eligible cases (n = 367), diagnosed with BE or BE with dysplasia,
with 577 controls. The second study compared eligible cases (n = 881), diagnosed with oesophageal
carcinoma of different types and location, with 1,507 controls. Median intake of choline in each
quartile in controls ranged between 380 and 1,171 mg/day. After adjustment for potential
confounders, choline intake was not associated with risk of BE or oesophageal cancers.
In a prospective cohort study with a follow-up of 22 years, Richman et al. (2012) examined the
association between total intake of choline (via foods and supplements) and risk of fatal prostate
cancer in 47,896 men, aged 40–75 years, and free of cancer diagnosis at baseline. After adjustment
for potential confounders, the highest quintile of choline intake (median 509 mg/day) was positively
associated with risk of fatal prostate cancer (hazard ratio (HR): 1.70; 95% CI: 1.18–2.45, p
trend = 0.005).
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In two large prospective cohorts with a follow-up of up to 22 years, Kotsopoulos et al. (2010)
investigated the relationship between total intake of choline (via foods and supplements) and risk of
ovarian cancer, among 159,957 women, aged 25–55 years at enrolment. In both cohorts, choline
cutpoints ranged between about 250–270 mg/day (lowest quintile) and 339–367 mg/day (highest
quintile). After adjustment for potential confounders, choline intake was not associated with risk of
ovarian cancer.
The Panel notes that choline intake was not associated with risk of oesophageal cancer in one
reference on two case–control studies or with risk of ovarian cancer in two cohorts followed prospectively,
while it was positively associated with risk of prostate cancer in one large prospective cohort study.
5.2.3.4. Conclusions
The Panel concludes that the available data on associations between choline intake and cancers of
various sites are either inconsistent or limited and cannot be used to derive DRVs for choline.
5.2.4. Neural tube defects
In a US population-based case–control study, Shaw et al. (2004) investigated the relationship
between periconceptional intake of choline and risk of NTDs, in 653 cases (liveborn, stillborn or
electively terminated) identiﬁed from hospital and medical records (in 1989–1991), compared with 644
controls randomly selected from the same geographical area. Dietary choline intake of the mothers
(not taking supplements with choline) in the 3 months before conception was estimated
retrospectively. The authors analysed 424 FFQs from mothers of NTD cases (161 with anencephaly,
242 with spina biﬁda, 21 with other NTD phenotypes) and 440 FFQs of controls. After adjustments for
potential confounders, a signiﬁcantly decreased risk of all NTDs was found for quartiles 2–4 of
periconceptional intake of choline compared to the lowest quartile (< 290 mg/day), e.g. for the fourth
quartile (> 498 mg choline/day) OR: 0.49; 95% CI: 0.27–0.90.
In another US population-based case–control study, Carmichael et al. (2010) investigated the
relationship between periconceptional intake of choline and risk of NTDs in 189 cases of spina biﬁda
and 141 cases of anencephaly (liveborn, stillborn, electively terminated) identiﬁed from hospital and
medical records (in 1999–2003), compared to 625 controls randomly selected from the same
geographical area. Dietary choline intake of the mothers in the 2 months before/after conception was
estimated retrospectively (8–10 months after delivery). After adjustments for potential confounders,
periconceptional intake of choline (supplements excluded) below the 25th percentile (< 293 mg/day)
and above the 75th percentile (> 506 mg/day) was not associated with a higher or lower risk for
anencephaly and spina biﬁda, compared to a choline intake between the 25th and 75th percentiles.
Polymorphisms in genes for enzymes (CHKA, MTHFD1 and CCT) involved in choline metabolism
may inﬂuence the risk of NTDs independently of maternal choline intake (Appendix C and Section 2.5),
but such information is not available for the studies cited above.
The Panel notes that the association between choline intake and risk of NTDs was inconsistent in
the two case–control studies available, and that such association may be inﬂuenced by the intake of
other nutrients and the genotype of the mother. The Panel concludes that the data on choline intake
and risk of NTDs cannot be used to derive DRVs for choline.
5.2.5. Cognition
The only RCT, then the prospective observational studies (ﬁrst in adults, then in children) are
described below.
In a double-blind RCT, Cheatham et al. (2012) investigated the relationship between maternal PC
supplementation during and after pregnancy (in women that, for most of them, had been investigated
by Fischer et al. (2010b)) and several measures of cognition in the infants. From 18 weeks of
gestation to 90 days post partum, 140 healthy women (Section 2.3.3, 2.3.6.3, 2.4.1.2, 2.5.1, 5.1.3)
received either 750 mg/day of choline (as PC, n = 49 included in the analysis) or a placebo (n = 50
included in the analysis), in addition to a diet providing a mean of about 360 mg/day choline (assessed
at 30 weeks of gestation and 45 days post partum). Infants (n = 99) were breast-fed for at least
45 days, and were assessed for short-term visuospatial memory (with a Delayed Response Task), long-
term episodic memory (with a deferred imitation task), language development (with the Mac-Arthur
Bates Short Form Vocabulary Checklist) and global development (with the Mullen Scales of Early
Learning) at 10 and 12 months of age. There were no signiﬁcant differences between the groups on
any of the cognitive assessments at either age.
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In a prospective cohort study, Poly et al. (2011) investigated the association between habitual dietary
intake of choline and performance at a neuropsychological test battery or brain morphology, assessed by
MRI, in 1,391 men and women (aged 36–83 years) without dementia at baseline. Choline intake was
estimated in 1991–1995 with the Harvard FFQ, and again in 1998–2001 when a neuropsychological test
battery and a brain MRI scan were also administered. Factor analysis was used to identify four cognitive
factors (verbal memory, visual memory, verbal learning and executive function) from the numerous
individual neuropsychological tests. Mean choline intake was about 322 mg/day in both periods. After
adjustment for potential confounders, performance on the verbal memory and visual memory factors
were signiﬁcantly better with higher choline intake in 1998–2001 (p < 0.01) but there were no signiﬁcant
effects for verbal learning and executive function. No signiﬁcant association between choline intake
(either period) and total cranium brain volume was found.
In a prospective prebirth cohort in 2,128 pregnant women included at less than 22 weeks of
gestation, Villamor et al. (2012) investigated the relationship between maternal total intake of choline
(via foods and supplements), assessed with an FFQ during the ﬁrst and second trimesters of
pregnancy, and performance on cognitive tests in their children (n = 1,210) at 3 years of age. The
cognitive tests included the Peabody Picture Vocabulary Test III and the Wide Range Assessment of
Visual Motor Abilities. Maternal intake of choline (mean  SD) was 332  63 and 325  64 mg/day in
the ﬁrst and second trimesters, respectively. There was no association between maternal choline
intake at either trimester and cognitive outcomes, after adjustment for potential confounders.
However, in this same cohort, Boeke et al. (2013) assessed 890 children with complete data at the
age of 7 years for visual memory (measured with the Wide Range Assessment of Memory and
Learning Second Edition (WRAML2), Design and Picture Memory subtests) and both verbal and
non-verbal intelligence, measured with the Kaufmann Brief Intelligence Test, Second Edition (KBIT-2)).
The top quartile of second trimester maternal choline intake (median (range): 392 (364–806) mg/day)
was signiﬁcantly associated with a WRAML2 score 1.4 points higher (95% CI: 0.5–2.4, p trend = 0.003)
than the bottom quartile (median (range): 260 (141–288) mg/day), after adjustment for potential
confounders. The association was not statistically signiﬁcant for the ﬁrst trimester maternal choline
intake. Comparing the top quartile of second trimester maternal intake with the ﬁrst quartile, the effect
estimate for the child non-verbal KBIT-2 score was 3.5 (95% CI: 0.1–6.9; p trend = 0.06).
The Panel notes that one RCT found no difference in four cognitive parameters investigated in
infants, at 10 and 12 months of age, whose mothers had consumed 750 mg/day choline or placebo in
addition to their choline intake from the diet during the third trimester. The Panel also notes that
available data on the relationship between choline intake and cognition in adults are limited. The
Panel also notes the discrepancy in the results of a prospective cohort study, investigating the
relationship between maternal choline intake during the ﬁrst and second trimesters of pregnancy and
cognitive outcomes in the children, when these children were aged three or 7 years. The
Panel considers that this might suggest that to investigate the effects of prenatal choline supply on
visual memory of the children, long-term observations are needed, and that the available evidence is
insufﬁcient to demonstrate a causal relationship. The Panel concludes that the data on choline intake
and cognition cannot be used to derive DRVs for choline.
5.2.6. Conclusion on choline intake and health consequences
In studies pointing to an association of higher choline intake with a reduced risk for a certain
outcome (i.e. risk of liver steatosis or of NTDs, one study each), the beneﬁcial effect was associated
with choline intakes between about 400 and 500 mg/day. However, one adverse health outcome
(higher risk of prostate cancer in one study) was associated with similar choline intakes (Section 5.2).
The Panel concludes that the data on choline intake and health outcomes are either limited or
inconsistent or do not show a signiﬁcant association, and, therefore, cannot be used to derive DRVs
for choline. There is a lack of data on choline intake in infants in the second half year of life and
children and on associations between choline intake and health outcomes in children that could be
used to set requirement for choline in these age groups.
6. Data on which to base dietary reference values
6.1. Adults
Mean observed intakes of healthy adults of all ages in Europe ranged from about 270 to 470 mg
choline/day (Section 3.2.1), and the midpoint of this range is around 370 mg/day.
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The Panel notes that choline depletion/repletion studies (Section 5.1.1) indicate large variability in
dietary choline requirement. The Panel also notes that the variability in choline requirement due to
differences in sex, polymorphisms of genes coding for enzymes involved in choline and folate
metabolism, nutritional and hormonal status, and likely the composition of the gut microbiome, pose a
difﬁculty for dose-ﬁnding studies in a sufﬁciently large sample of the population (Section 2). The
Panel concludes that choline depletion/repletion studies do not provide sufﬁciently precise data to
calculate Average Requirements (ARs) and PRIs for dietary choline.
The Panel also notes that there is only one depletion/repletion study that reports the choline
amounts that were needed/sufﬁcient to reverse the signs of choline deﬁciency in a small number of
subjects (Fischer et al., 2007). In this study, out of 25 subjects who showed signs of choline deﬁciency
after experimental choline depletion and for whom the amount of choline needed to replete them was
available, about two-thirds (or about 70%) of subjects needed up to about 400 mg choline/70-kg bw
per day for repletion (Table 2, Section 5.1.2).
Finally, the Panel chose to set an AI for choline for adults based on data on observed mean intakes
in healthy populations, investigated in 12 national surveys undertaken in nine countries in the EU
between 2000 and 2011 (Section 3.2.1), and in consideration of the amount of choline needed to
replete about two-thirds (or about 70%) of choline-depleted subjects who showed signs of organ
dysfunction and for whom data on the amount of choline needed for repletion were available (Fischer
et al., 2007). The Panel is aware of the inherent uncertainty of the chosen value. However, assuming
that the choline requirement of the 18 subjects of this study who did not show signs of choline
deﬁciency after a restriction of the choline intake to 50 mg/70-kg bw per day for 6 weeks, will also be
covered by an intake of 400 mg/day, the Panel considers this choice of 400 mg/day to be a safe and
conservative approach.
Although premenopausal women may have a lower requirement for dietary choline than
postmenopausal women, in connection with a potential stimulation of the PEMT pathway by
oestrogen, the Panel is not aware of quantitative data with regard to the enhanced activity of the
PEMT. Although ranges of estimated mean observed choline intake in healthy populations in the EU are
slightly lower in women than men (Section 3.2.1), and considering that the data from the one
depletion/repletion study (Fischer et al., 2007) are insufﬁcient to conclude on sex-speciﬁc DRVs, the
Panel considered it unnecessary to give sex-speciﬁc AIs for adults.
The Panel proposes an AI of 400 mg/day for all adults.
6.2. Infants
Considering that there is no evidence for an insufﬁcient choline intake of fully breast-fed infants
during the ﬁrst 6 months of life, the amount of choline provided in human milk is considered to be
adequate. Considering a choline concentration of 145 mg/L (average of two studies on full-term
infants) and assuming a mean milk transfer of 0.8 L/day during the ﬁrst 6 months of lactation in
exclusively breastfeeding women (Butte et al., 2002; FAO/WHO/UNU, 2004; EFSA NDA Panel, 2009),
the estimated choline intake of fully breast-fed infants during the ﬁrst 6 months of life would be
116 mg/day, rounded up to 120 mg/day (Section 2.3.6.3).
In order to estimate the AI of infants aged 7–11 months by upwards extrapolation from the
calculated choline intake for exclusively breast-fed infants from birth to 6 months, allometric scaling
was applied. The Panel calculated averages of the median weights of male and female infants, aged
3 months (6.1 kg) and 9 months (8.6 kg); the median weight-for-age data came from the WHO
Growth Standards (WHO Multicentre Growth Reference Study Group, 2006).
AIinfants 711 months ¼ choline intakeinfants 06 months 
weightinfants 711 months
weightinfants 06 months
 0:75
This calculation yields a value of 155, which gives an AI of 160 mg/day after rounding (Table 3).
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6.3. Children
The Panel recognises the limited number of data on age-speciﬁc choline intake in European
children and uncertainty surrounding these data (Section 3.2). The Panel chose to derive AIs for all
children by downwards extrapolation from the AI for adults (400 mg/day) (Section 6.1), taking into
account that this AI for adults was based on data on observed intakes in the EU, and the amounts of
choline needed to replete about two-thirds (or about 70%) of choline-depleted adults who had
developed signs of organ dysfunction and for whom data on choline amounts needed for repletion
were available. This downwards extrapolation was carried out based on reference body weights using
allometric scaling with age-dependent growth factors, and applying the 0.75 power of body mass to
correct for differences in the metabolically active body mass of subjects of different sizes. Although it
is not known if the choline requirement is related to energy metabolism, the Panel considers that
allometric scaling, which results in a higher percentage of the adult AI than when the actual body
weight is used, is justiﬁed to cover the need for choline in the development of organs and their
composition.
No data are available that would justify different AIs for boys and girls.
The AIs were calculated by using the following equation
AIchild ¼ AIadults 
weightchild
weightadults
 0:75
 ð1þ growth factorÞ
For the calculations (Table 4), median body weights of boys and girls (van Buuren et al., 2012)
and median body weights of 18- to 79-year-old men and women were used, based on measured
body heights of 16,500 men and 19,969 women in 13 EU Member States and assuming a BMI of
22 kg/m2 (see Appendix 11 in EFSA NDA Panel (2013b)). The following growth factors have been
applied: 0.25 for boys and girls aged 1–3 years, 0.06 for boys and girls aged 4–6 years, 0.13 for
boys and girls aged 7–10 years, 0.11 for boys and 0.08 for girls aged 11–14 years and 0.08 for
boys and 0.03 for girls aged 15–17 years. Growth factors were calculated as the proportional
increase in protein requirement for growth relative to the maintenance requirement at the different
ages (EFSA NDA Panel, 2012). The value for each age group corresponds to the mean of values
for the years included (EFSA NDA Panel, 2014a). Calculated AIs were rounded to the nearest 10.
Although the calculations yielded an AI for children aged 15–17 years that was higher (i.e.
410 mg/day) than the value set for adults (i.e. 400 mg/day), the Panel considered that there was
no reason for such a difference, thus decided to set the same AI for children aged 15–17 years
and adults.
The AIs for children are supported by total choline intake mean estimates in the EU (Section 3.2.1),
i.e. estimates ranging from 151 to 210 mg/day (midpoint: 180 mg/day) in children aged 1 to
< 3 years, from 177 to 304 mg/day (midpoint: 240 mg/day) in children aged 3 to < 10 years, from
244 to 373 mg/day (midpoint: 308 mg/day) among children aged 10 to < 18 years.
The Panel is aware that the AI for children aged 1–3 years (140 mg/day) is lower than the AI for
infants aged 7–11 months (160 mg/day, Section 6.2). This difference is due to the approaches used
for calculation (upwards extrapolation from the high choline intake of breast-fed infants from birth to
6 months, for infants aged 7–11 months vs downwards extrapolation from the AI for adults, for
children aged 1–17 years). The Panel considers this higher AI for infants aged 7–11 months compared
with children aged 1–3 years to be justiﬁed by a high demand for choline for phospholipid synthesis by
the developing brain of infants (Section 2.3.4).
Table 3: Reference body weights and Adequate Intake (AI) of choline for infants aged 7–11 months
Age Reference body weight (kg) AI (mg/day)
7–11 months 8.6(a) 160
(a): Average of the median weight-for-age of male or female infants, respectively, aged 9 months according to the WHO Growth
Standards (WHO Multicentre Growth Reference Study Group, 2006).
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6.4. Pregnancy
The Panel concludes that calculation of choline transfer from the mother to the fetus and choline
accretion in the fetus and placenta during the duration of pregnancy is not feasible to set DRVs for
dietary choline during pregnancy due to a lack of data (Sections 2.3.3, 2.3.4 and 5.1.3.5). Although
the available intervention studies on choline supplementation in the second half of pregnancy indicate
that pregnant women may need more choline than non-pregnant women (Section 5.1.3.5), the data
are not sufﬁcient to allow an estimate of the additional requirement for dietary choline in pregnant
women (above that of non-pregnant women).
Therefore, the Panel proposes to calculate the additional choline intake needed by pregnant woman,
by isometric scaling from the AI of non-pregnant women (400 mg/day, Section 6.1), using the reference
body weight for non-pregnant women and the mean gestational increase in body weight. The reference
body weight of 18–79-year-old women (58.5 kg) was previously calculated from the measured body
heights of 19,969 women in 13 EU Member States and assuming a BMI of 22 kg/m2 (see Appendix 11 in
EFSA NDA Panel (2013b)). A mean gestational increase in body weight of 12 kg, for women with a
singleton pregnancy and a pre-pregnancy BMI in the range between 18.5 and 24.9 kg/m2, was
also previously considered (EFSA NDA Panel, 2013b). Thus, the calculation was based on the
equation below:
AIpregnant ¼ AInonpregnant  70:5 kg58:5 kg
 
¼ 480 mg/day
The Panel notes that the calculation by allometric scaling (as applied in Section 6.3) would lead to a
value of 460 mg/day. The Panel, however, notes that the amount obtained by isometric scaling
(480 mg/day) is the same as the lower dose in one intervention study on pregnant women (recruited
at 27 weeks of gestation) (Yan et al., 2012) (Sections 2.3.6.1, 2.4.1.2 and 5.1.3). In view of the weak
evidence and the minimal differences between the two scaling approaches, the Panel chose the value
of 480 mg/day.
The Panel notes that this AI is higher than the mean choline intake of pregnant women (around
350 mg/day), observed either in the Latvian survey for which individual data were available to EFSA
(Section 3.2.1) or in another publication outside the EU (Canada, Section 3.2.2).
The Panel proposes an AI of pregnant women of 480 mg choline/day. The Panel points out that
this AI applies to the whole duration of pregnancy.
Table 4: Reference body weights and Adequate Intakes (AIs) of choline for children aged
1–17 years
Age
(years)
Reference body
weights (kg)
Growth
factors
Calculated AIs
(mg/day) Calculated average AI
(mg/day)
Proposed AIs
(mg/day)
Boys Girls Boys Girls Boys Girls
1–3 12.2(a) 11.5(a) 0.25 0.25 137.68 147.61 142.65 140
4–6 19.2(b) 18.7(b) 0.06 0.06 164.05 180.25 172.15 170
7–10 29.0(c) 28.4(c) 0.13 0.13 238.27 262.88 250.58 250
11–14 44.0(d) 45.1(d) 0.11 0.08 319.97 355.42 337.70 340
15–17 64.1(e) 56.4(e) 0.08 0.03 412.83 400.86 406.84 400(f)
(a): Average of the median weight-for-age of male or female children aged 24 months according to the WHO Growth Standards
(WHO Multicentre Growth Reference Study Group, 2006).
(b): Average of the median weight of male or female children aged 5 years (van Buuren et al., 2012).
(c): Average of the median weight of male or female children aged 8.5 years (van Buuren et al., 2012).
(d): Average of the median weight of male or female children aged 12.5 years (van Buuren et al., 2012).
(e): Average of the median weight of male or female children aged 16 years (van Buuren et al., 2012).
(f): The Panel decided to set the same AI for children aged 15–17 years and for adults.
Adult body weight used for calculations: 68.1 kg for men and 58.5 kg for women (median body weight of 18–79-year-old men
and women, respectively, based on measured body heights of 16,500 men and 19,969 women in 13 EU Member States and
assuming a BMI of 22 kg/m2, see Appendix 11 in EFSA NDA Panel (2013b)).
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6.5. Lactation
The Panel concludes that the available intervention studies in lactating women (Sections 2.3.6.3
and 5.1.3.5) provide evidence that increased maternal choline intake enhances the concentration of
choline in breast milk and that lactating women may need more choline than non-lactating women,
but the data are not sufﬁcient to allow an estimate of the additional requirement for dietary choline in
lactating women (above that of non-lactating women).
For lactating women, the Panel decides to set a higher AI than for non-lactating women, by
compensating for the secretion of choline in breast milk. Approximately 120 mg choline is secreted per
day in human milk during the ﬁrst 6 months of exclusive breastfeeding, considering an average
concentration of total choline (free choline and choline compounds) in mature breast milk from
mothers of full-term infants of 145 mg/L and a mean milk transfer during the ﬁrst 6 months of
lactation in exclusively breastfeeding women of 0.8 L/day (Section 2.3.6.3). The Panel proposes an
additional AI of 120 mg/day above the AI for non-lactating women (400 mg/day), without correcting
for intestinal absorption due to lack of data (Section 2.3.1). Thus, the Panel sets an AI of 520 mg/day
for lactating women.
Conclusions
The Panel considers that none of the biomarkers of choline intake or status is suitable to derive
DRVs for choline. The Panel concludes that ARs and PRIs for choline cannot be derived for adults,
infants and children, and therefore deﬁnes AIs. For all adults, the Panel sets an AI based on the
midpoint of the range of observed mean choline intakes in healthy populations in the EU (about
370 mg/day), and in consideration of the results of a depletion/repletion study in which about 70% of
the depleted subjects who had developed signs of organ dysfunction were repleted with an intake of
about 400 mg/70-kg bw per day. For all infants aged 7–11 months, the Panel proposes an AI based on
upwards extrapolation by allometric scaling from the estimated choline intake of exclusively breast-fed
infants from birth to 6 months. For all children aged 1–17 years, the Panel derives AIs by downwards
extrapolation from the adult AI, by allometric scaling, applying growth factors. These AIs are
supported by estimated mean total choline intake in Europe. When applying allometric scaling,
differences in reference body weight were taken into account. The Panel considers it unnecessary to
give sex-speciﬁc AIs for adults, infants or children. For pregnant women, the Panel derives an AI by
extrapolation from the AI for adults using isometric scaling and the mean gestational increase in body
weight. For lactating women, the amount of choline secreted per day in human milk during the ﬁrst
6 months of exclusive breastfeeding is added to the AI for non-lactating women (Table 5).
Recommendations for research
The Panel suggests to undertake further research on:
• the identiﬁcation of frequency of SNPs in genes coding for enzymes involved in choline
metabolism that inﬂuence the requirement for dietary choline in the EU;
• the quantiﬁcation of the increase in choline requirement, in carriers of alleles with increased
need for choline;
• choline content of EU foods, to obtain better quantitative data on choline intake in Europe;
Table 5: Summary of Dietary Reference Values for choline
Age Adequate Intakes (mg/day)
7–11 months 160
1–3 years 140
4–6 years 170
7–10 years 250
11–14 years 340
15–17 years 400
Adults 400
Pregnancy 480
Lactation 520
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• biomarkers of choline status;
• criteria on which to base choline sufﬁciency in different populations;
• the consequences of the epigenetic modiﬁcations of genes involved in hormonal and vascular
physiology and their expression following changes in choline intake during pregnancy;
• quantitative assessment of choline transfer from mother to fetus;
• quantiﬁcation of the incorporated choline compounds in the body or in different organs during
fetal development.
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ARA arachidonic acid
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BE Barrett’s oesophagus
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BMI body mass index
bw body weight
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CDP cytidine 5-diphosphate
CEPT choline/ethanolaminephosphotransferase
CHK choline kinase
CHKA choline kinase A
CHKB choline kinase B
CHD coronary heart disease
CHDH choline dehydrogenase or choline oxidase
CHT choline transporter
CI conﬁdence interval
CK creatine (phospho)kinase
COMET single-cell gel electrophoresis
CpG cytosine–phosphate–guanine
CPT cytidine 5-diphosphate-choline
CRC colorectal cancer
CRH corticotropin releasing hormone
CRP C-reactive protein
CT computerised tomography
CTL1 choline transporter-like protein 1
CTP cytidine triphosphate
CVD cardiovascular disease
DFE dietary folate equivalent
DHA docosahexaenoic acid
DMG dimethylglycine
DNA Deoxyribonucleic acid
DRV Dietary Reference Value
dTMP deoxythymidine monophosphate
EAR Estimated Average Requirement
FFQ food frequency questionnaire
FMO3 ﬂavin-containing monooxygenase isoform 3
GC–MS gas chromatography–mass spectrometry
GGT c-glutamyltransferase
GPC glycerophosphocholine
HClO4 perchloric acid
Hcy homocysteine
HDL high-density lipoprotein
HPLC high-performance liquid chromatography
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HR hazard ratio
IOM US Institute of Medicine of the National Academy of Sciences
KBIT-2 Kaufmann Brief Intelligence Test, Second Edition
Km Michaelis constant
LC–MS/MS liquid chromatography–tandem mass spectrometry
LC-PUFA long-chain polyunsaturated fatty acid
LDH lactate dehydrogenase
LDL low-density lipoprotein
LOAEL Lowest Observed Adverse Effect Level
Met methionine
MG methylglycine
MIDA multiple isotopomer distribution analysis
MM molecular mass
MRI magnetic resonance imaging
mRNA messenger RNA
MRS magnetic resonance spectroscopy
MS methionone synthase
MTHFD1 5,10-methylenetetrahydrofolate dehydrogenase 1
MTHFR methylenetetrahydrofolate reductase
NAFLD non-alcoholic fatty liver disease
NDA EFSA Panel on Dietetic Products, Nutrition and Allergies
NHS Nurses’ Health Study
NHANES National Health and Nutrition Examination Survey
NORCCAP Norwegian Colorectal Cancer Prevention
NR3C1 nuclear receptor subfamily 3 group C member 1 (glucocorticoid receptor)
N.S. not signiﬁcant
NTD neural tube defect
OCT organic cation transporter
OR odds ratio
P percentile
PC phosphatidylcholine
PChol phosphocholine
PE phosphatidylethanolamine
PEMT phosphatidylethanolamine N-methyltransferase
PL phospholipase
PRI Population Reference Intake
Q quintile
RCT randomised controlled trial
RDA Recommended Dietary Allowance
RFC1 reduced folate carrier 1
RNA ribonucleic acid
RR relative risk
rs number Reference SNP cluster ID
SAH S-adenosylhomocysteine
SAH-H S-adenosylhomocysteine hydrolase
SAM S-adenosyl-methionine
SCF Scientiﬁc Committee for Food
SD standard deviation
SEM standard error of the mean
sFLT1 soluble fms-like tyrosine kinase 1
SLC44A1 solute carrier family 44 member 1 (choline transporter)
SLC5A7 solute carrier family 5 member 7 (choline transporter)
SNP single nucleotide polymorphism
SPM sphingomyelin
TAG triacylglycerol
tHcy total homocysteine
THF tetrahydrofolate
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TLC thin-layer chromatography
TMA trimethylamine
TMAO trimethylamine-N-oxide
TMP thymidine monophosphate (thymidylic acid)
TTMA total trimethylamine
TUNEL terminal deoxynucleotidyl transferase dUTP nick end labeling
UL Tolerable Upper Intake Level
USDA United States Department of Agriculture
VLDL very low-density lipoproteins
WHO World Health Organization
WRAML2 Wide Range Assessment of Memory and Learning Second Edition
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Appendix C – SNPs of genes coding for enzymes involved in choline
metabolism and their impact on choline requirement and/or risk to
develop organ dysfunction while being fed a low-choline diet
Enzyme gene rs number
Base pair
and change
Comments
Phosphatidylethanolamine
methyltransferase (PEMT)
(about 100 SNPs)
rs12325817
rs4646343
rs37601188
744G?C
C?A
G?A
Three SNPs that decrease the oestrogen responsive
PEMT induction (da Costa et al., 2014) associated with
increased risk of choline deﬁciency on choline depletion.
May increase the dietary requirement of choline.
Eighteen of 23 female carriers of the variant
rs12325817 allele developed organ dysfunction on
choline depletion (OR of 25; 95% CI 2.0–256.0;
p = 0.002), but men did not (da Costa et al., 2006a).
Fischer et al. (2010a) found a gene dose–response
relationship in 27 premenopausal women to develop
signs of choline deﬁciency on choline depletion: 80%,
43% and 13% with two, one and zero variant alleles,
respectively, developed liver dysfunction. Eleven of 22
postmenopausal women subjected to the standard
choline depletion/repletion experiment who received
oestrogen were four times less likely to develop choline-
deﬁciency associated liver dysfunction than 11 women
who received placebo
The rs12325817 CC genotype was associated with an
increased risk for breast cancer mortality compared to
the GG genotype (OR 1.30, 95% CI 1.01–1.67) (Xu
et al., 2008)
About 75% of the North Carolina population is carrier of
at least one rs12325817 C allele and 18% are
homozygous for the variant allele (Corbin and Zeisel,
2012). The rs12325817 allele was associated in 92% of
64 women with a rs4646343 allele (Kohlmeier et al.,
2005; da Costa et al., 2006a; Resseguie et al., 2011)
rs7946(3) +5465G?A Despite 30% loss of function, no increased susceptibility
to choline deﬁciency (da Costa et al., 2006a). The PEMT
rs79463 SNP is found more frequently in people with
fatty liver consuming a low-choline diet (Ivanov et al.,
2009) and in 67.9% of patients with NAFLD (healthy
subjects 40.7%) (Song et al., 2005)
Attenuates rise in plasma Hcy in men with the MTHFR
677TT genotype (Caudill et al., 2009)
Gene frequency in 43 Mexican-American women: GG 3,
GA 19, AA 21 (Ivanov et al., 2009)
All effect alleles of PEMT occur frequently in American
subjects of European origin (homozygosity 24–60%),
followed by Mexican origin (9-12%) and least in subjects
of Asian or African descent (da Costa et al., 2014)
Carrier status of offspring without effect on umbilical cord
blood choline and its metabolites (Visentin et al., 2015)
Methylenetetrahydrofolate
dehydrogenase 1
(MTHFD1)
rs2236225 1958G?A Decreases the availability of methyl-THF for Hcy
remethylation and increases reliance on choline-derived
methyl groups. May increase the dietary requirement of
choline and reduce the synthesis of PC (Ivanov et al.,
2009): in a choline depletion/repletion study on 54
healthy adults (n = 26 men and n = 28 women), more
than half of the participants developed organ
dysfunction associated with choline deﬁciency. Signs of
choline deﬁciency were signiﬁcantly (> 15 times in
premenopausal women) more likely to occur in subjects
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Enzyme gene rs number
Base pair
and change
Comments
who were carriers of the A allele of the SNP rs2236225
of MTHFD1 (OR 7.0; 95% CI 2.0–25.0, p < 0.01) than
in non-carriers during the low-choline diet, unless they
were also treated with a folic acid supplement
(Kohlmeier et al., 2005)
Homozygous mothers for the SNP were found to have a
1.5–2-fold increased risk of carrying a child with an NTD
(Brody et al., 2002)
Carrier status of offspring without effect on umbilical cord
blood choline and its metabolites (Visentin et al., 2015)
63% of subjects investigated in North Carolina possessed
at least one allele of this SNP and 11% were homozygous
carriers (da Costa et al., 2006a; Corbin and Zeisel, 2012)
Choline dehydrogenase
(CHDH)
rs9001 +114A?C Carriers may be protected against organ dysfunction
upon choline depletion (OR 0.2; 95% CI 0.05–0.7,
p = 0.03) (da Costa et al., 2006a)
rs12676 +233G?T May increase the dietary requirement of choline in
carriers of the variant associated with increased
susceptibility to choline deﬁciency upon choline depletion
in premenopausal women (OR 20.0; 95% CI 1.0–282.0;
p = 0.04) (da Costa et al., 2006a)
The Tallele was associated with an increased risk (OR
1.19, 95% CI 1.00-1.41) for breast cancer compared to
the major G allele (Xu et al., 2008)
Forty and 75% lower ATP concentration in sperm of men
with GT (n = 18) and TT (n = 5) genotypes compared to
the GG (n = 17) genotype, respectively (Johnson et al.,
2012). The TT genotype is present in 9% of the North
Carolina population, the prevalence of the GTgenotype is
45% (Johnson et al., 2012)
Carrier status of offspring without effect on umbilical cord
blood choline and its metabolites (Visentin et al., 2015)
Betainehomocysteine
methyltransferase (BHMT)
rs3733890 +742G?A Not associated with susceptibility to choline deﬁciency
(da Costa et al., 2006a)
This polymorphism was not associated with breast
cancer risk (Xu et al., 2008), but with a reduced risk of
breast cancer mortality (Xu et al., 2009). Carrier status
of offspring without effect on umbilical cord blood
choline and its metabolites (Visentin et al., 2015)
Choline kinase A (CHKA) rs7928739
rs10791957
rs2512612
A?C
A?C
A?G
Three SNPs associated with a decreased risk for organ
dysfunction on choline depletion in homozygotes (da
Costa et al., 2014)
Frequency is highest in subjects of African descent
followed by Asian and European origin and least
frequent in subjects of Mexican origin (da Costa et al.,
2014)
In a case–control study on 103 cases of spina biﬁda and
of 338 controls, the CHK SNP (rs7928739) genotype
with at least one C allele was associated with a reduced
risk of spina biﬁda (OR = 0.60, 95% CI = 0.38–0.94
(Enaw et al., 2006)
rs6591331 A?T Associated with increased risk for organ dysfunction in
postmenopausal women on choline depletion in
homozygotes (da Costa et al., 2014)
Dietary Reference Values for choline
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Enzyme gene rs number
Base pair
and change
Comments
Choline kinase B (CHKB) rs1557502 G?A Associated with an increased risk for muscle damage on
choline depletion (da Costa et al., 2014). Most frequent
in subjects of African descent, least frequent with
European origin (da Costa et al., 2014). Nine of ten
subjects who developed muscle damage were
heterozygous or homozygous carriers of the effect
alleles for SLC44A1 rs2771040 (G) and CHKB rs1557502
(A)
CTP:phosphocholine
cytidyltransferase (CCT)
rs939883 T?A In a case–control study on 103 cases of spina biﬁda and
of 338 controls, the CCT rs939883 genotype AA was
associated with an increased risk of spina biﬁda
(OR = 1.89, 95% CI = 0.97–3.67) (Enaw et al., 2006)
Solute carrier 44A1
(choline transporter)
(SLC44A1)
rs7873937
rs2771040
rs6479313
rs16924529
rs3199966
C?G
A?G
C?G
G?A
A?C
Associated with an increased risk for muscle damage on
choline depletion with a low-choline diet (da Costa
et al., 2014). Nine of ten subjects who developed
muscle damage were heterozygous or homozygous
carriers of the effect alleles for SLC44A1 rs2771040 (G)
and CHKB rs1557502 (A)
Most frequent in subjects of African descent, least
frequent with Asian origin (da Costa et al., 2014)
Methylenetetrahydrofolate
reductase (MTHFR)
rs1801133 677C?T Thermolabile enzyme, increases the reliance on choline-
derived methyl groups for Hcy remethylation when
folate intake is insufﬁcient (Yan et al., 2011).
Signiﬁcantly increased plasma Hcy, decreased plasma
PC and SPM with low folate status/intake in both men
and women with either CC (n = 28) or TT (n = 17)
genotype, but no change in plasma choline and
leukocyte global DNA methylation. Women with the TT
genotype had a 10.3% increase in plasma PC while
consuming adequate amounts of folate and choline. No
changes in plasma PC in response to diet in subjects
with the CC genotype (Abratte et al., 2009)
In 60 healthy men, 29 with the TT genotype and 31
with the CC genotype, an intake of 300 mg choline/day
for 12 weeks was sufﬁcient to maintain liver and kidney
function, but 438 µg DFE/day did not prevent a rise in
plasma tHcy in subjects with the TT genotype. Under
these conditions, choline supplementation (up to
1,900 mg/day) had no effect on plasma tHcy and serum
folate concentrations. Choline intake decreased DNA
methylation in subjects with the CC genotype but not in
TT subjects (Solis et al., 2008; Veenema et al., 2008;
Caudill et al., 2009)
Carrier status of offspring without effect on umbilical
cord blood choline and its metabolites (Visentin et al.,
2015)
TT genotype frequency varies between ethnic groups
(2–35%)
rs1801131 1298A?C Reduced enzyme activity; no association with risk for
choline deﬁciency in choline depletion/repletion studies
(Kohlmeier et al., 2005)
ATP: adenosine triphosphate; BHMT: betaine-homocysteine methyltransferase; CCT/CTP:phosphocholine cytidyltransferase;
CHDH: choline dehydrogenase; CHK: choline kinase; CI: conﬁdence interval; DFE: dietary folate equivalent;
DNA: deoxyribonucleic acid; Hcy: homocysteine; MTHFD1: 5,10-methylene-tetrahydrofolate dehydrogenase 1;
MTHFR: methylene-tetrahydrofolate reductase; NAFLD: non-alcoholic fatty liver disease; NTD: neural tube defect; OR: odds ratio;
PC: phosphatidylcholine; PEMT: phosphatidylethanolamine N-methyltransferase; rs number: Reference SNP cluster ID;
SLC44A1: solute carrier family 44 member 1 (choline transporter); SNP: single-nucleotide polymorphism; SPM: sphingomyelin;
THF: tetrahydrofolate.
Dietary Reference Values for choline
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r
ge
no
ty
pi
ng
M
TH
FD
1,
PE
M
T,
CH
D
H
an
d
fo
r
ch
an
ge
in
ex
pr
es
si
on
w
ith
lo
w
-c
ho
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en
ts
P
ar
ti
ci
p
an
ts
D
es
ig
n
/d
u
ra
ti
o
n
R
es
u
lt
s
C
o
m
m
en
t
Fi
sc
he
r
et
al
.
(2
01
0a
)
4
Lo
w
-c
ho
lin
e
re
la
te
d
or
ga
n
dy
sf
un
ct
io
n,
in
re
la
tio
n
to
nu
m
be
r
of
al
le
le
s
of
rs
12
32
58
17
in
pr
em
en
op
au
sa
l
w
om
en
,
an
d
in
re
la
tio
n
to
oe
st
ro
ge
n
in
po
st
m
en
op
au
sa
l
w
om
en
Li
ve
r
fa
t
by
M
R
I,
CK
,
AS
T,
AL
T
Pl
as
m
a
ch
ol
in
e
(m
et
ab
ol
ite
s)
G
en
ot
yp
in
g
fo
r
PE
M
T
rs
12
32
58
17
A
:
n
=
27
pr
em
en
op
au
sa
lw
om
en
,
ag
e
18
–4
9
ye
ar
s.
B
:
n
=
22
po
st
m
en
op
au
sa
l
w
om
en
,
ag
e
50
–
73
ye
ar
s,
ra
nd
om
is
ed
to
re
ce
iv
e
oe
st
ro
ge
n
(B
1
)
or
pl
ac
eb
o
(B
2
).
H
ea
lth
y
M
et
ab
ol
ic
un
it
St
an
da
rd
is
ed
de
pl
et
io
n/
re
pl
et
io
n
B
as
el
in
e
di
et
(1
0
da
ys
):
55
0
m
g
ch
ol
in
e/
70
-k
g
bw
pe
r
da
y
D
ep
le
ti
o
n
di
et
(u
p
to
42
da
ys
):
<
50
m
g
ch
ol
in
e/
70
-k
g
bw
pe
r
da
y
R
ep
le
ti
o
n
di
et
:
55
0–
85
0
m
g/
70
-k
g
bw
pe
r
da
y
fo
r
up
to
10
da
ys
.
If
si
gn
s
of
or
ga
n
dy
sf
un
ct
io
n
di
d
no
t
re
so
lv
e
af
te
r
10
da
ys
of
re
pl
et
io
n
di
et
:
ad
lib
itu
m
di
et
fo
r
2
w
ee
ks
A
m
o
n
g
p
re
m
en
o
p
au
sa
l
w
o
m
en
:
11
/2
7
de
ve
lo
pe
d
ch
ol
in
e
de
ﬁc
ie
nc
y/
or
ga
n
dy
sf
un
ct
io
n.
Th
er
e
w
as
a
do
se
–r
es
po
ns
e
ef
fe
ct
of
rs
12
32
58
17
on
th
e
ris
k
of
ch
ol
in
e
re
la
te
d
or
ga
n
dy
sf
un
ct
io
n:
80
%
,
43
%
,
an
d
13
%
of
w
om
en
w
ith
2,
1,
or
0
al
le
le
s,
re
sp
ec
tiv
el
y,
de
ve
lo
pe
d
or
ga
n
dy
sf
un
ct
io
n
du
rin
g
th
e
lo
w
-c
ho
lin
e
di
et
A
m
o
n
g
p
o
st
m
en
o
p
au
sa
l
w
o
m
en
:
O
nl
y
2/
11
(1
8%
)
w
ho
re
ce
iv
ed
oe
st
ro
ge
n
(B
1)
an
d
8/
11
(7
3%
)
w
ho
re
ce
iv
ed
pl
ac
eb
o
(B
2)
,
de
ve
lo
pe
d
or
ga
n
dy
sf
un
ct
io
n
du
rin
g
th
e
lo
w
-c
ho
lin
e
di
et
D
ie
ta
ry
re
qu
ire
m
en
t
fo
r
ch
ol
in
e
is
hi
gh
er
in
po
st
m
en
op
au
sa
lw
om
en
(b
ec
au
se
of
th
ei
r
lo
w
er
oe
st
ro
ge
n
co
nc
en
tr
at
io
ns
)
th
an
in
pr
em
en
op
au
sa
l
w
om
en
Ch
ol
in
e
re
qu
ire
m
en
ts
fo
r
bo
th
gr
ou
ps
of
w
om
en
ar
e
fu
rt
he
r
in
cr
ea
se
d
by
rs
12
32
58
17
.
80
%
of
ho
m
oz
yg
ou
s
w
om
en
de
ve
lo
p
or
ga
n
dy
sf
un
ct
io
n
on
th
e
de
pl
et
io
n
di
et
vs
43
%
of
th
os
e
w
ith
on
e
co
py
an
d
13
%
of
w
om
en
ho
m
oz
yg
ou
s
fo
r
th
e
w
ild
-t
yp
e
N
o
oe
st
ro
ge
n
vs
oe
st
ro
ge
n
in
cr
ea
se
s
fo
ur
fo
ld
th
e
ris
k
fo
r
or
ga
n
dy
sf
un
ct
io
n
on
th
e
de
pl
et
io
n
di
et
.
O
es
tr
og
en
m
iti
ga
te
s
th
e
ef
fe
ct
of
th
e
PE
M
T
SN
P.
O
es
tr
og
en
m
ay
de
cr
ea
se
ch
ol
in
e
re
qu
ire
m
en
t
in
po
st
m
en
op
au
sa
lw
om
en
Sh
a
et
al
.
(2
01
0)
3
M
et
ab
ol
om
ic
pr
oﬁ
lin
g
to
pr
ed
ic
t
or
ga
n
dy
sf
un
ct
io
n
w
ith
de
ﬁc
ie
nt
ch
ol
in
e
in
ta
ke
Li
ve
r
fa
t
by
M
R
I
CK
,
AS
T,
AL
T
Pl
as
m
a
ch
ol
in
e
(m
et
ab
ol
ite
s)
,
M
et
,
H
cy
,
sa
rc
os
in
e,
D
M
G
,
cy
st
ei
ne
,
cy
st
at
hi
on
in
e,
M
et
ab
ol
om
ic
an
al
ys
is
of
pl
as
m
a
n
=
53
,
n
=
30
w
om
en
,
ag
e
18
–7
0
ye
ar
s,
he
al
th
y
M
et
ab
ol
ic
un
it
St
an
da
rd
is
ed
de
pl
et
io
n/
re
pl
et
io
n
de
si
gn
B
as
el
in
e
di
et
(1
0
da
ys
):
55
0
m
g
ch
ol
in
e/
70
-k
g
bw
pe
r
da
y
D
ep
le
ti
o
n
di
et
(u
p
to
42
da
ys
):
<
50
m
g
ch
ol
in
e/
70
-k
g
bw
pe
r
da
y
R
ep
le
ti
o
n
di
et
(≥
3
da
ys
,
O
rg
an
d
ys
fu
n
ct
io
n
B
as
el
in
e
d
ie
t:
9
(1
7%
)
de
ve
lo
pe
d
fa
tt
y
liv
er
(n
=
4)
or
m
us
cl
e
dy
sf
un
ct
io
n
(n
=
5)
,
w
ith
ou
t
sp
ec
ia
l
m
et
ab
ol
om
e
D
ep
le
ti
o
n
(n
=
44
):
23
fa
tt
y
liv
er
,
5
m
us
cl
e
dy
sf
un
ct
io
n
M
et
ab
ol
om
ic
pr
oﬁ
le
s
of
su
bj
ec
ts
at
ba
se
lin
e
co
ul
d
pr
ed
ic
t
th
e
de
ve
lo
pm
en
t
of
liv
er
dy
sf
un
ct
io
n
w
he
n
de
pr
iv
ed
of
di
et
ar
y
ch
ol
in
e
D
ie
ta
ry
R
ef
er
en
ce
V
al
u
es
fo
r
ch
o
lin
e
w
w
w
.e
fs
a.
eu
ro
p
a.
eu
/e
fs
aj
o
u
rn
al
68
EF
SA
Jo
u
rn
al
20
16
;1
4(
8)
:4
48
4
A
u
th
o
r
A
im
o
f
in
ve
st
ig
at
io
n
O
u
tc
o
m
e
m
ea
su
re
m
en
ts
P
ar
ti
ci
p
an
ts
D
es
ig
n
/d
u
ra
ti
o
n
R
es
u
lt
s
C
o
m
m
en
t
(≥
55
0
m
g/
70
-k
g
bw
pe
r
da
y)
H
ig
he
r
pl
as
m
a
H
cy
,
cy
st
ei
ne
,
cy
st
at
hi
on
in
e,
ke
to
-a
ci
ds
at
ba
se
lin
e
in
su
bj
ec
ts
w
ho
la
te
r
de
ve
lo
p
fa
tt
y
liv
er
Ch
ol
in
e
de
ﬁc
ie
nc
y
in
cr
ea
se
d
pl
as
m
a
ca
rn
iti
ne
an
d
ac
yl
-
ca
rn
iti
ne
,
de
cr
ea
se
d
py
rid
ox
at
e
Ba
se
lin
e
pl
as
m
a
ch
ol
in
e
ha
s
no
pr
ed
ic
tiv
e
va
lu
e
Sp
en
ce
r
et
al
.
(2
01
1)
4
Ch
ol
in
e
de
ﬁc
ie
nc
y
an
d
he
pa
tic
st
ea
to
si
s
an
d
gu
t
m
ic
ro
bi
om
e
Li
ve
r
fa
t
by
M
R
I
CK
AS
T,
AL
T
Se
qu
en
ci
ng
of
th
e
16
S
R
N
A
ba
ct
er
ia
lg
en
es
in
st
oo
l;
ge
no
ty
pi
ng
of
PE
M
T
pr
om
ot
er
SN
P
rs
12
32
58
17
n
=
15
fe
m
al
es
,
ag
e
no
t
re
po
rt
ed
,
he
al
th
y
St
an
da
rd
is
ed
de
pl
et
io
n/
re
pl
et
io
n
de
si
gn
2
m
on
th
s:
B
as
el
in
e
di
et
(1
0
da
ys
):
55
0
m
g
ch
ol
in
e/
70
-k
g
bw
pe
r
da
y
D
ep
le
ti
o
n
di
et
(u
p
to
42
da
ys
):
<
50
m
g
ch
ol
in
e/
70
-k
g
bw
pe
r
da
y
R
ep
le
ti
o
n
di
et
(1
0
da
ys
,
(≥
85
0
m
g/
70
-k
g
bw
pe
r
da
y)
N
o
st
at
is
tic
al
ly
si
gn
iﬁ
ca
nt
ge
ne
ra
l
m
ic
ro
bi
al
co
nv
er
ge
nc
e
w
ith
ch
ol
in
e
de
pl
et
io
n
H
os
t
fa
ct
or
s
as
w
el
la
s
gu
t
ba
ct
er
ia
re
sp
on
d
to
di
et
ar
y
ch
ol
in
e
de
ﬁc
ie
nc
y,
bu
t
in
di
vi
du
al
m
ic
ro
bi
ot
a
pe
rs
is
t
al
th
ou
gh
al
l
su
bj
ec
ts
co
ns
um
ed
th
e
sa
m
e
di
et
s
da
Co
st
a
et
al
.
(2
01
1)
3
+
4
PC
-D
H
A
pl
as
m
a
co
nc
en
tr
at
io
n
us
ed
as
a
no
n-
in
va
si
ve
m
ar
ke
r
of
liv
er
PE
M
T
ac
tiv
ity
Pl
as
m
a
D
H
A,
PC
-D
H
A,
ra
tio
PC
-D
H
A/
to
ta
lP
C
n
=
72
,
ag
e
18
-
70
ye
ar
s;
n
=
20
m
en
;
n
=
52
w
om
en
of
w
hi
ch
n
=
25
po
st
m
en
op
au
sa
l
an
d
n
=
27
pr
em
en
op
au
sa
l
St
an
da
rd
is
ed
de
pl
et
io
n/
re
pl
et
io
n
de
si
gn
B
as
el
in
e
di
et
(1
0
da
ys
):
55
0
m
g
ch
ol
in
e/
70
-k
g
bw
pe
r
da
y
D
ep
le
ti
o
n
di
et
(u
p
to
42
da
ys
):
<
50
m
g
ch
ol
in
e/
70
-k
g
bw
pe
r
da
y
R
ep
le
ti
o
n
di
et
70
%
of
th
e
su
bj
ec
ts
po
ss
es
s
at
le
as
t
on
e
PE
M
T
rs
12
32
58
17
al
le
le
Pl
as
m
a
ra
tio
PC
-D
H
A/
to
ta
l
PC
hi
gh
er
in
pr
em
en
op
au
sa
lw
om
en
th
an
m
en
or
po
st
m
en
op
au
sa
l(
at
ba
se
lin
e
an
d
ev
en
w
he
n
on
a
lo
w
-c
ho
lin
e
di
et
)
Pl
as
m
a
PC
-D
H
A/
to
ta
lP
C
at
ba
se
lin
e
an
d
PE
M
T
ac
tiv
ity
in
liv
er
:
lo
w
er
in
pr
em
en
op
au
sa
lw
om
en
ho
m
oz
yg
ou
s
fo
r
th
e
rs
12
32
58
17
po
ly
m
or
ph
is
m
in
th
e
PE
M
T
ge
ne
D
ie
ta
ry
R
ef
er
en
ce
V
al
u
es
fo
r
ch
o
lin
e
w
w
w
.e
fs
a.
eu
ro
p
a.
eu
/e
fs
aj
o
u
rn
al
69
EF
SA
Jo
u
rn
al
20
16
;1
4(
8)
:4
48
4
A
u
th
o
r
A
im
o
f
in
ve
st
ig
at
io
n
O
u
tc
o
m
e
m
ea
su
re
m
en
ts
P
ar
ti
ci
p
an
ts
D
es
ig
n
/d
u
ra
ti
o
n
R
es
u
lt
s
C
o
m
m
en
t
da
Co
st
a
et
al
.
(2
01
1)
3
+
4
Id
en
tiﬁ
ca
tio
n
of
ef
fe
ct
al
le
le
s
of
SN
Ps
kn
ow
n
to
in
ﬂu
en
ce
di
et
ar
y
re
qu
ire
m
en
t
fo
r
ch
ol
in
e
D
N
A
co
nc
en
tr
at
io
n
by
sp
ec
tr
om
et
ry
;
ge
no
ty
pi
ng
of
al
le
le
s
n
=
79
,
18
-7
0
ye
ar
s
ol
d;
n
=
26
m
en
n
=
53
w
om
en
of
w
hi
ch
n
=
26
po
st
an
d
n
=
27
pr
em
en
op
au
sa
l
St
an
da
rd
is
ed
de
pl
et
io
n/
re
pl
et
io
n
de
si
gn
B
as
el
in
e
di
et
(1
0
da
ys
):
55
0
m
g
ch
ol
in
e/
70
-k
g
bw
pe
r
da
y
D
ep
le
ti
o
n
di
et
(u
p
to
42
da
ys
):
<
50
m
g
ch
ol
in
e/
70
-k
g
bw
pe
r
da
y
R
ep
le
ti
o
n
di
et
Ef
fe
ct
al
le
le
s
id
en
tiﬁ
ed
of
SN
Ps
in
ge
ne
s
fo
r
th
e
ch
ol
in
e
tr
an
sp
or
te
r
(S
LC
44
A1
)
an
d
ch
ol
in
e
ki
na
se
A
an
d
B
(s
ee
Ap
pe
nd
ix
C)
Ch
ol
in
e
de
ﬁc
ie
nc
y
re
la
te
d
or
ga
n
dy
sf
un
ct
io
n
(li
ve
r
or
m
us
cl
e:
50
/7
9,
in
cl
ud
in
g
20
of
26
po
st
m
en
op
au
sa
lw
om
en
,
11
of
27
pr
em
en
op
au
sa
l
w
om
en
19
of
26
m
en
29
of
79
he
al
th
y
su
bj
ec
ts
di
d
no
t
de
ve
lo
p
or
ga
n
dy
sf
un
ct
io
n
w
hi
le
co
ns
um
in
g
a
lo
w
-c
ho
lin
e
di
et
fo
r
6
w
ee
ks
*S
am
e
nu
m
be
rs
in
th
e
co
lu
m
n
“a
ut
ho
r”
in
di
ca
te
re
fe
re
nc
es
pr
ov
id
in
g
da
ta
fr
om
th
e
sa
m
e
co
ho
rt
.
AL
T:
al
an
in
e
am
in
ot
ra
ns
fe
ra
se
;
AS
T:
as
pa
rt
at
e
am
in
ot
ra
ns
fe
ra
se
;
CH
D
H
:
ch
ol
in
e
de
hy
dr
og
en
as
e;
CI
:
co
nﬁ
de
nc
e
in
te
rv
al
;
CK
:
cr
ea
tin
e
ki
na
se
;
CO
M
ET
:
si
ng
le
-c
el
lg
el
el
ec
tr
op
ho
re
si
s;
CT
:
co
m
pu
te
ris
ed
to
m
og
ra
ph
y;
D
FE
:
di
et
ar
y
fo
la
te
eq
ui
va
le
nt
;
D
H
A:
do
co
sa
he
xa
en
oi
c
ac
id
;
D
M
G
:
di
m
et
hy
lg
ly
ci
ne
;
D
N
A:
de
ox
yr
ib
on
uc
le
ic
ac
id
;
LD
H
:
la
ct
at
e
de
hy
dr
og
en
as
e;
M
et
:
m
et
hi
on
in
e;
M
G
:
m
et
hy
lg
ly
ci
ne
;
M
R
I:
m
ag
ne
tic
re
so
na
nc
e
im
ag
in
g;
M
TH
FD
1:
5,
10
-m
et
hy
le
ne
-t
et
ra
hy
dr
of
ol
at
e
de
hy
dr
og
en
as
e
1;
M
TH
FR
:
M
et
hy
le
ne
-t
et
ra
hy
dr
of
ol
at
e
re
du
ct
as
e;
N
.S
.:
no
t
si
gn
iﬁ
ca
nt
;
O
R
:
od
ds
ra
tio
;
PC
:
ph
os
ph
at
id
yl
ch
ol
in
e;
PE
M
T:
ph
os
ph
at
id
yl
et
ha
no
la
m
in
e
N
-m
et
hy
ltr
an
sf
er
as
e;
R
FC
1:
re
du
ce
d
fo
la
te
ca
rr
ie
r
1;
R
N
A:
rib
on
uc
le
ic
ac
id
;
rs
nu
m
be
r:
R
ef
er
en
ce
SN
P
cl
us
te
r
ID
;
SA
H
:
S-
ad
en
os
yl
ho
m
oc
ys
te
in
e;
SA
M
:
S-
ad
en
os
yl
-m
et
hi
on
in
e;
SL
C4
4A
1:
so
lu
te
ca
rr
ie
r
fa
m
ily
44
m
em
be
r
1
(c
ho
lin
e
tr
an
sp
or
te
r)
;
SN
P:
si
ng
le
-n
uc
le
ot
id
e
po
ly
m
or
ph
is
m
;
tH
cy
:
to
ta
lh
om
oc
ys
te
in
e;
TU
N
EL
:
te
rm
in
al
de
ox
yn
uc
le
ot
id
yl
tr
an
sf
er
as
e
m
ed
ia
te
d
dU
TP
ni
ck
en
d
la
be
lli
ng
.
w
w
w
.e
fs
a.
eu
ro
p
a.
eu
/e
fs
aj
o
u
rn
al
70
EF
SA
Jo
u
rn
al
20
16
;1
4(
8)
:4
48
4
D
ie
ta
ry
R
ef
er
en
ce
V
al
u
es
fo
r
ch
o
lin
e
